

Jae Hee Cheon, M.D., Ph.D.

Department of Internal Medicine, Yonsei University College of Medicine
50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea
E-mail: GENIUSHEE@yuhs.ac

Education

2006 **Ph.D.**, Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
2001 **M.S.**, Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
1996 **M.D.**, Medicine, Seoul National University College of Medicine, Seoul, Korea (license No.: 59883)

Postgraduate Training

2004-2005 **Clinical and Research Fellow**, Internal Medicine, Seoul National University Hospital
2003-2004 **Public Health Care Doctor**, National Cancer Center, Ilsan, Korea
2001-2003 **Military service**
1997-2000 **Medical Residency**, Internal Medicine, Seoul National University Hospital
1996-1997 **Intern**, Seoul National University Hospital

Academic appointments

2016.03 – present **Professor**, Yonsei University College of Medicine, Seoul, Korea
2011.08 – 2012.07 **Visiting scientist**, Mucosal Immunology Section, International Vaccine Institute, Seoul, Korea
2011.03 – 2016.02 **Associate Professor**, Yonsei University College of Medicine, Seoul, Korea
2007.03 – 2011.02 **Assistant Professor**, Yonsei University College of Medicine, Seoul, Korea
2006 – 2007.02 **Instructor** of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Board Certification

2007 Board of Gastroenterology and Hepatology
2006 Board of Gastrointestinal Endoscopy
2001 Board of Internal Medicine

Institutional Committee Activities

2023.03 – present **Director**, Inflammatory Bowel Center, Severance Hospital, Seoul, Korea
2023.03 – present **Member**, Human Microbiome Center, Yonsei University College of Medicine, Seoul, Korea
2014 – present **Research Committee** of Yonsei University College of Medicine
2007 – present **Institutional Review Board** of Severance Hospital (IRB chair, panel 6)

Memberships

Member, The Korean Society of Gastroenterology
Member, The Korean Society of Hepatology
Member, The Korean Society of Gastrointestinal Endoscopy
Member, The Korean Association for the Study of Intestinal Diseases
Member, The Korean Society of Helicobacter and Upper GI Diseases Research
Member, The Korean Society of Neurogastroenterology and Motility
Member, The Korean Study Group of Mucosal Immunology
Member, The Korean Society of Internal Medicine
Member, The Korean Society of Behcet's disease

Editorial Boards and Councils

Deputy Editor of Intestinal Research
Associate Editor of Gut and Liver
Associate Editor of Yonsei Medical Journal
Associate Editor of Clinical Endoscopy
Contributing Associate Editors-in-Chief, World Journal of Gastroenterology
Editorial Board member of Journal of Gastroenterology and Hepatology
Editorial Board member of Digestive Diseases and Sciences
Editorial Board member of the Korean Journal of Gastroenterology
Editorial Board Member of the Korean Society of Helicobacter and Upper GI Diseases Research
Editorial Board member of Intestinal inflammatory diseases
Board of directors of Korean Society for Behçet's disease
Board of directors of The Korean Association of Immunologists
Board of directors of The Korean Society of Clinical Nutrition
Board member of Asian Organization of Crohn's and Colitis 2022.3-
Secretary General of The Korean Association of Study for Intestinal Diseases 2023.3-
Secretary General of The Korean Society for Behçet's disease 2021.10-

Honors and Awards

2023 Professor of the Year 2023, Department of Internal Medicine, Yonsei University College of Medicine
2021 KGIF Award Best Abstracts and Presentations in KDDW 2021
2020 Professor of the Year 2020, Department of Internal Medicine, Yonsei University College of Medicine
2018 The best research award, Korean FDA research and development exhibition
2017 50th Yuhan Medical Award Grand Prize
2014 Distinguished Professor of the Year (Education field), Yonsei University College of Medicine
2014 Best professor for referral patient treatment
2014 Academic award-grand for correspondence author, Internal Medicine, Yonsei University College of Medicine
2012 The best prolific award, Internal Medicine, Yonsei University College of Medicine
2012 Outstanding results in basic research field from Ministry of Education
2012 Distinguished Professor of the Year (Clinical research field), Yonsei University College of Medicine
2012 Asian-Pacific Gastroenterology Association, Award of Emerging Leadership Lecturer
2011 Young investigator award, Yonsei University College of Medicine
2011 Distinguished Professor of the Year (Research field), Yonsei University
2010 Hamchoon Academic award, Internal Medicine, Seoul National University College of Medicine
2010 Academic award, The Korean Association for the Study of Intestinal Diseases
2008 Academic award, Internal Medicine, Yonsei University College of Medicine
2007 The best professor of the year (clinical field), Yonsei University College of Medicine
2007 Janssen award, The Korean Society of Gastroenterology
2006 The best paper award, The Korean Association for the Study of Intestinal Diseases
2005 The best paper award, The Korean Society of Hepatology

GCP training

| | |
|------------|---|
| 2023/09/28 | 2023 Severance IRB workshop (Advanced training course for GCP) |
| 2022/02/24 | 2022 Severance IRB workshop (Advanced training course for GCP) |
| 2021/02/25 | Severance GCP training |
| 2020/09/28 | 질병관리청 ‘생명윤리법 관련 온라인 교육과정’(2.5h) 수료 |
| 2020/03/25 | GCP(R2) (NIDA Clinical Trials Network) |
| 2019/06/19 | 2019 Advanced training course for Clinical Trials in Severance hospital |
| 2018/02/02 | 2018 Investigator GCP Workshop in Severance hospital |
| 2017/02/23 | 2017 Investigator GCP Workshop in Severance hospital |
| 2016/11/25 | 14th IRB workshop “Efficient and high-quality IRB review; based on up-to date GCP” |
| 2016/08/30 | 2016 Investigator GCP Workshop in Severance hospital |
| 2015/08/18 | 2015 Investigator GCP Workshop in Severance hospital |
| 2015/07/23 | CITI Collaborative Institutional Training Initiative completed (GCP-Drugs, ICH-Focused) |
| 2014/07/23 | CITI Collaborative Institutional Training Initiative completed (GCP course) |
| 2013/07/19 | Completion of Investigator GCP workshop for KFDA inspection |
| 2012/12/28 | 9th IRB workshop “Strengthening IRB functions through quality management” |
| 2012/07/19 | CITI Collaborative Institutional Training Initiative completed (Advanced one) |
| 2011/04/19 | CITI Collaborative Institutional Training Initiative completed (Basic course) |
| 2011/01/28 | Completion of Investigator GCP workshop |
| 2011/01/28 | Clinical Research Ethics and IRB with Faculty Workshop of YUHS |
| 2011/01/15 | 7th IRB workshop “GCP and In-depth review of clinical research” |
| 2010/09/10 | 6th IRB workshop “Strengthening Capability for IRB review including bioethics and GCP” |
| 2010/01/14 | Completion of Investigator GCP workshop |

Grants

| | |
|------|--|
| 2023 | Industrial Strategic Technology Development Program funded by the Ministry of Trade, Industry and Energy, (20018770) |
| 2023 | National Research Foundation of Korea funded by the Ministry of Science and ICT, (NRF-2020R1A2C2003638) |
| 2022 | Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HR14C0006070022) |
| 2022 | Korea Medical Device Development Fund funded by the Ministry of Science and ICT, (KD000235) |
| 2022 | National Research Foundation of Korea funded by the Ministry of Science and ICT, (NRF-2020R1A2C2003638) |
| 2022 | Technology Innovation Program funded by the Ministry of Trade, Industry and Energy, (20018770) |
| 2021 | Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry(IPET) funded by the Ministry of Agriculture, Food and Rural Affairs (918003044SB050) |
| 2021 | Research of Korea Centers for Disease Control and Prevention funded by Research of Korea Centers for Disease Control and Prevention (2019-ER6905-02) |
| 2021 | Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HR14C0006070021) |
| 2021 | Korea Medical Device Development Fund funded by (KMDF_PR_20200901_0235-01) |
| 2021 | National Research Foundation of Korea funded by the Ministry of Science and ICT, (NRF-2020R1A2C2003638) |
| 2020 | Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry(IPET) funded by the Ministry of Agriculture, Food and Rural Affairs (918003043SB050) |
| 2020 | Research of Korea Centers for Disease Control and Prevention funded by the Ministry of Health & Welfare, (2019-ER6905-01) |
| 2020 | Research of Korea Centers for Disease Control and Prevention funded by the Ministry of Health & Welfare, (2019-ER6905-01) |
| 2020 | Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HR14C0006070020) |
| 2020 | National Research Foundation of Korea funded by the Ministry of Science and ICT, (NRF-2020R1A2C2003638) |
| 2019 | Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry(IPET) funded by the Ministry of Agriculture, Food and Rural Affairs (918003042SB050) |
| 2019 | Research of Korea Centers for Disease Control and Prevention funded by the Ministry of Health & Welfare, (2019-ER6905-00) |
| 2019 | Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI18C0094010019) |
| 2019 | National Research Foundation of Korea funded by the Ministry of Science and ICT, (NRF-2017R1A2B4001848) |
| 2018 | Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry(IPET) funded by the Ministry of Agriculture, Food and Rural Affairs (918003041SB050) |

2018 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI18C0094010018)
2018 National Research Foundation of Korea funded by the Ministry of Science and ICT, (NRF-2017R1A2B4001848)
2017 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI12C0130020017)
2017 Ministry of Food and Drug Safety funded by the Ministry of Food and Drug Safety (DY0002255875-15182한임평507-1)
2017 National Research Foundation of Korea funded by the Ministry of Education (21A20132200004)
2017 National Research Foundation of Korea funded by the Ministry of Science and ICT, (NRF-2017R1A2B4001848)
2016 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HR14C0006040016)
2016 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI12C0130020016)
2016 Ministry of Food and Drug Safety funded by the Ministry of Food and Drug Safety (DY0000224061-15182한임평507-1)
2015 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI12C0130020015)
2015 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HR14C0006040015)
2015 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI13C1345000015)
2015 National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (NRF-2013R1A2A2A01067123)
2014 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI12C0130020014)
2014 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HR14C0006040014)
2014 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI13C1345000014)
2014 National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (NRF-2013R1A2A2A01067123)
2013 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI12C0130020013)
2013 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (HI13C1345000013)
2013 National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (NRF-2013R1A2A2A01067123)
2013 National Research Foundation of Korea funded by the Ministry of Education (NRF-2011-0025131)
2012 a faculty research grant of Yonsei University College of Medicine for 2012
2012 a faculty research grant of Yonsei University College of Medicine for 2012 (Guiturami grant)
2012 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (A120176120002)
2012 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (A120770120001)
2012 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (A111428120001)
2012 ational Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2011-0025131)
2011 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (A110671)
2011 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (A111428)
2011 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (A080588)
2011 National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (전106A1110)
2011 National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2011-0025131)
2010 Yonsei University College of Medicine, Internal Medicine Research Grant 2010
2010 a faculty research grant of Yonsei University College of Medicine for 2010
2010 Korea Health Technology R&D Project funded by the Ministry of Health & Welfare, (A080588)
2010 National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2009-0069149)
2010 National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (전106A1110)
2009 BumSuk Academic Research Fund of 2009
2009 Korea Health Technology R&D Project funded by the Ministry for Health, Welfare and Family Affairs (A090898)
2009 Korea Health Technology R&D Project funded by the Ministry for Health, Welfare and Family Affairs (A080588)
2009 National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2009-0069149)
2008 Korea Health Technology R&D Project funded by the Ministry for Health, Welfare and Family Affairs (A084943)
2008 Korea Health Technology R&D Project funded by the Ministry for Health, Welfare and Family Affairs (A080588)
2008 National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2008-331-E00105)
2007 National Research Foundation of Korea funded by the Ministry of Education&Human Resources Development (NRF-2006-331-E00112)
2007 A 2007 grant of Korean Association for the Study of Intestinal Diseases (KASID)
2007 a faculty research grant of Yonsei University College of Medicine for 2007 (6-20070224)
2006 National Research Foundation of Korea funded by the Ministry of Education&Human Resources Development (NRF-2006-331-E00112)
2006 Yonsei University Research Fund of 2006 (6-2006-0108)
2006 Yonsei University College of Medicine, Internal Medicine Research Grant 2006
2006 A 2006 Altana grant in association with the Korean Society of Gastrointestinal Endoscopy
2006 A grant from the Institute of Gastroenterology, Yonsei University College of Medicine
2006 A faculty research grant from Yonsei University College of Medicine for 2006 (6-2006-0042)

Seminars and Conferences (selected)

- 2023 APNM, Jeju *"The role of inflammation in irritable bowel syndrome"*
- 2023 50th symposium of FCH in Mongolia, Ulaanbatar *"Targeting Mucosal Healing for CD in Real Practice"*
- 2023 11th Annual Meeting of AOCC, Busan, *"The Future of Intestinal Research: Another Big Leap for the AOCC"*
- 2023 11th Annual Meeting of AOCC, Busan, *"The Effectiveness of Probiotics in the Treatment of IBD"*
- 2022 KAI, Incheon, *"Immunometabolism in Inflammatory bowel diseases"*
- 2022 10th Annual Meeting of AOCC, Tokyo *"Triggering Receptor Expressed on Myeloid Cells-1 Agonist regulates Intestinal Inflammation via Cd177+ Neutrophils"*
- 2021 TDDW, Taiwan, *"Deep-Learning System for Real-time Differentiation between Crohn's Disease, Intestinal Behçet's Disease, and Intestinal Tuberculosis"*
- 2021 9th Annual Meeting of AOCC, China *"Transitional care for patients with inflammatory bowel disease"*
- 2020 JSIBD, Tokyo *"Application of genotyping in the use of thiopurines"*
- 2020 8th Annual Meeting of AOCC, Seoul *"Optimizing outcomes through control of gut and systemic inflammation in ulcerative colitis (UC): Tight monitoring & inflammation control in UC"*
- 2019 7th Annual Meeting of AOCC, Taiwan, *"What Clinician Should Know about the Genetic Results"*
- 2018 Trinity ME conference of Janssen, Taiwan, *"Manage IBD with biologics"*
- 2018 APDW *"Shifting paradigm in IBD management- Things you should know when managing elderly IBD patients"*
- 2017 8th Annual Meeting of JSIBD, Japan, *"Multidisciplinary approach to IBD care"*
- 2016 AOCC, Invited speaker, Kyoto; *"Intestinal Homeostasis by Gut Microbiota via Innate Immune Receptors"*
- 2016 17th International Conference on Behçet's Disease, Matera, Italy; *"Differential Diagnosis"*
- 2015 KSBD (The Korean Society for behçet's disease) symposium, Seoul
- 2015 Immunology summit, Hong Kong; *"Treat to target therapy in IBD"*
- 2015 DDW, invited speaker, USA; *"Differential diagnosis between Crohn's disease, Intestinal behçet's disease and intestinal tuberculosis"*
- 2014 The Fall conference of Korean Association of Immunologists, invited speaker, Seoul; *"IBD pathogenesis"*
- 2014 the 8th International symposium of Rare diseases-Rare disease research consortium, invited speaker, Seoul
- 2014 KAIST Science Technology Convergence Symposium, invited speaker, Daejeon, KAIST; *"Intestinal homeostasis by gut microbiota via innate immune homeostasis"*
- 2014 JDDW (Japan Digestive Disease Week), invited speaker, Kobe, Japan
- 2014 IDEN 2014, invited speaker, Seoul
- 2014 9th Congress of ECCO (European Crohn's and colitis Organization), invited speaker, Copenhagen/Denmark
- 2014 2nd AOCC meeting, invited speaker, Seoul; *"The impact of genetic alterations on clinical characteristics of IBD"*
- 2013 the 9th IGICS meeting, invited speaker, Tokyo
- 2013 the 48th Seminar of Korean Society of Gastrointestinal Endoscopy, Invited Speaker, Seoul
- 2013 International IBD Genetic Consortium meeting, invited speaker, Shanghai; *"IBD genetics update in Korea."*
- 2013 IDEN(International Digestive Endoscopy Network) 2013 with 12th KJSGE, invited speaker, Seoul
- 2013 AOCC (Asian Organization for Crohn's & Colitis), Invited speaker, Tokyo; *"Mucosal Healing after Clinical Remission Predicts Long-term Outcomes in Patients with Intestinal Behçet's Disease"*
- 2012 the 6th Japan-Korean joint IBD symposium, Invited Speaker, Tokyo
- 2012 International Ulcer Week 2012, invited speaker, Tokyo
- 2012 APDW 2012, invited speaker, Bangkok
- 2011 The 1st Asian IBD symposium, Invited speaker, Tokyo
- 2010 the 5th Japan-Korean joint IBD symposium, Invited Speaker, Seoul
- 2010 the 4th Society of Gastrointestinal Intervention meeting, Invited Speaker, Seoul
- 2010 International Gastrointestinal Consensus Symposium, Invited speaker, Fukuoka, Japan
- 2009 the 4th Japan-Korean joint IBD symposium, Invited Speaker, Tokyo
- 2009 International Symposium of Yonsei Institute of Gastroenterology, Invited speaker, Seoul
- 2009 International Behçet's Disease Symposium, Invited speaker, Seoul
- 2008 the Asian-Pacific Digestive Disease Week, Speaker, Kobe, Japan
- 2007 the 3rd Japan-Korean joint IBD symposium, Invited Speaker, Seoul
- 2005 the Asian-Pacific Digestive Disease Week, Speaker, Seoul, Korea
- 2004 the Asian-Pacific Society of Liver Disease, Speaker, New Dehli, India

Patents

| | |
|------------|---|
| 2021.01.05 | Korea Patent 1025334690000, "Composition for preventing or treating inflammatory bowel disease" |
| 2020.08.25 | Korea Patent 1024656360000, "Apparatus and method of augmenting learning data for deep learning model which can automatically segment head and neck medical image" |
| 2020.07.20 | Korea Patent 1023555680000, "A Biomarker for diagnosing Intestinal Behcet's disease" |
| 2019.10.07 | Korea Patent 1023114720000, "Method for predicting regions of normal tissue and device for predicting regions of normal tissue using the same" |
| 2019.08.29 | Korea Patent 1022870110000, "Method for providing information of stent insertion and device using the same" |
| 2019.04.16 | Korea Patent 1022546680000, "A composition comprising GSTT1 protein or encoding gene thereof" |
| 2018.07.02 | Korea Patent 1020108990000, "Method for providing the information for predicting or diagnosing of inflammatory bowel disease using single nucleotide polymorphism to be identified from next generation sequencing screening" |
| 2017.05.16 | Korea Patent 1020108970000, "Method for providing the information for predicting or diagnosing of inflammatory bowel disease using single nucleotide polymorphism to be identified from next generation sequencing screening" |
| 2016.06.30 | Korea Patent 1018545230000, "Method for providing information on diagnosis or stage of lung cancer and kit using the same" |
| 2016.04.12 | Korea Patent 1017863220000, "System and method for monitoring radiation based on imaging" |
| 2015.11.13 | Korea Patent 1017912460000, "Prediction method for clinical characteristics of Crohn's disease" |
| 2015.06.16 | Korea Patent 1017241300000, "Biomarkers for Diagnosing Intestinal Behcet's Disease and Uses Thereof" |
| 2012.08.17 | Korea Patent 1013941970000, "Method of providing the information of single nucleotide polymorphism associated with inflammatory bowel disease" |
| 2012.03.13 | Korea Patent 1013451660000, "A method of providing the information of diagnosing bowel disease using Strem-1" |
| 2012.03.13 | Korea Patent 1014152580000, "A method of providing the information of diagnosing inflammatory diseases by determining methylation of the promoter region of stat-4 and a kit using the same method" |

Publications (ORCID: <https://orcid.org/0000-0002-2282-8904>)

- Ji JH, Kim HW, Park J, Park SJ, **Cheon JH**, Kim TI, Park JJ., Risk factors for post-polypectomy bleeding in patients with end-stage renal disease undergoing colonoscopic polypectomy, *Surg Endosc.* 2024 Feb;38(2):846-856. doi: 10.1007/s00464-023-10626-5. Epub 2023 Dec 11.
- Park J, Chun J, Park SJ, Park JJ, Kim TI, Yoon H, **Cheon JH.**, Effectiveness and Tolerability of Methotrexate Combined with Biologics in Patients with Crohn's Disease: A Multicenter Observational Study, *Dig Dis Sci.* 2024 Jan 13. doi: 10.1007/s10620-023-08237-0. Online ahead of print. (**corresponding author**)
- Park J, Park IS, Kim JH, Ji JH, Park SJ, Park JJ, Kim TI, Kim SW, **Cheon JH.**, New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases, *Therap Adv Gastroenterol.* 2024 Jan 27;17:17562848241227029. doi: 10.1177/17562848241227029. eCollection 2024. (**corresponding author**)
- Bae H, Seo N, Kang EA, **Cheon JH**, Lim JS, Kim MJ., Validation of the simplified magnetic resonance index of activity by using DWI without gadolinium enhancement to evaluate bowel inflammation in Crohn's disease, *Eur Radiol.* 2023 May;33(5):3266-3275. doi: 10.1007/s00330-023-09501-7. Epub 2023 Mar 11.
- Baumdick ME, Niehrs A, Degenhardt F, Schwerk M, Hinrichs O, Jordan-Paiz A, Padoan B, Wegner LHM, Schloer S, Zecher BF, Malsy J, Joshi VR, Illig C, Schröder-Schwarz J, Möller KJ; Hamburg Intestinal Tissue Study Group; Martin MP, Yuki Y, Ozawa M, Sauter J, Schmidt AH, Perez D, Giannou AD, Carrington M, Davis RS, Schumacher U, Sauter G, Huber S, Puelles VG, Melling N, Franke A; International Inflammatory Bowel Disease Genetics Consortium; Altfeld M, Bunders MJ., HLA-DP on Epithelial Cells Enables Tissue Damage by Nkp44(+) Natural Killer Cells in Ulcerative Colitis, *Gastroenterology.* 2023 Oct;165(4):946-962.e13. doi: 10.1053/j.gastro.2023.06.034. Epub 2023 Jul 15.
- Chang JY, Park SJ, Park JJ, Kim TI, **Cheon JH**, Park J., Impact of age at diagnosis on long-term prognosis in patients with intestinal Behçet's disease, *J Gastroenterol Hepatol.* 2023 Dec 27. doi: 10.1111/jgh.16449. Online ahead of print.
- Cheon JH**, Kim HS, Han DS, Kim SK, Shin SJ, Kim JS, Ye BD, Song GA, Lee Y, Kim Y, Lee Y, Kim WH; BEGIN Study Group., Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN), *Gut Liver.* 2023 Sep 15;17(5):777-785. doi: 10.5009/gnl220278. Epub 2022 Dec 29. (**1st author**)

8. **Cheon JH**, Paridaens K, Awadhi SA, Begun J, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Ryzewska G, Dignass AU, Travis SP., The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis, *Intest Res.* 2023 Jan;21(1):161-167. doi: 10.5217/ir.2022.00006. Epub 2022 Apr 18. **(1st author)**
9. **Cheon JH**., Past, present, and future of Intestinal Research, *Intest Res.* 2023 Jan;21(1):1-2. doi: 10.5217/ir.2023.00010. Epub 2023 Jan 31. **(corresponding author) (1st author)**
10. Han SJ, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, **Cheon JH**., Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy, *Yonsei Med J.* 2023 Feb;64(2):111-116. doi: 10.3349/ymj.2022.0264.
11. Hyun HK, Lee HW, Park J, Park SJ, Park JJ, Kim TI, Lee JS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU, **Cheon JH**., Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease, *Gut Liver.* 2023 May 19. doi: 10.5009/gnl220409. Online ahead of print. **(corresponding author)**
12. Jang J, Park J, Park SJ, Park JJ, **Cheon JH**, Kim TI., Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis, *Intest Res.* 2023 Oct;21(4):510-517. doi: 10.5217/ir.2022.00139. Epub 2023 May 31. **(corresponding author)**
13. Jung ES, Ellinghaus D, Degenhardt F, Meguro A, Khor SS, Mucha S, Wendorff M, Juzenas S, Mizuki N, Tokunaga K, Kim SW, Lee MG, Schreiber S, Kim WH, Franke A, **Cheon JH**., Genome-wide association analysis reveals the associations of NPHP4, TYW1-AUTS2 and SEMA6D for Behçet's disease and HLA-B*46:01 for its intestinal involvement, *Dig Liver Dis.* 2023 Nov 15:S1590-8658(23)01010-1. doi: 10.1016/j.dld.2023.10.021. Online ahead of print. **(corresponding author)**
14. Kang S, Kim J, Park A, Koh M, Shin W, Park G, Lee TA, Kim HJ, Han H, Kim Y, Choi MK, Park JH, Lee E, Cho HS, Park HW, **Cheon JH**, Lee S, Park B., TRIM40 is a pathogenic driver of inflammatory bowel disease subverting intestinal barrier integrity, *Nat Commun.* 2023 Feb 9;14(1):700. doi: 10.1038/s41467-023-36424-0. **(corresponding author)**
15. Kim JK, **Cheon JH**., Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study, *J Yeungnam Med Sci.* 2023 Jan;40(1):37-48. doi: 10.12701/jyms.2022.00031. Epub 2022 Apr 18. **(corresponding author)**
16. Kim SW, Lee JY, Lee HC, Ahn JB, Kim JH, Park IS, **Cheon JH**, Kim DH., Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn's Disease, *Gut Liver.* 2023 Nov 15;17(6):905-915. doi: 10.5009/gnl220308. Epub 2023 Feb 23.
17. Lee JY, Ma HW, Kim JH, Park IS, Son M, Ryu KH, Shin J, Kim SW, **Cheon JH**., Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function, *Gut Liver.* 2023 Sep 15;17(5):766-776. doi: 10.5009/gnl220159. Epub 2022 Sep 27. **(corresponding author)**
18. Lee MH, Li HJ, Wasuwanich P, Kim SE, Kim JY, Jeong GH, Park S, Yang JW, Kim MS, Yon DK, Lee SW, Koyanagi A, Jacob L, Kim EY, **Cheon JH**, Shin JI, Smith L., COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis, *Rev Med Virol.* 2023 Mar;33(2):e2414. doi: 10.1002/rmv.2414. Epub 2022 Dec 11. **(corresponding author)**
19. Ma HW, Kim JM, Kim DH, Park IS, Kim JH, Park KC, Seo DH, Kim JH, Che X, Kim TI, **Cheon JH**, Kim SW., Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer, *Cancer Gene Ther.* 2023 May;30(5):694-703. doi: 10.1038/s41417-022-00585-9. Epub 2022 Dec 28. **(1st author)**
20. Park IS, Kim JH, Yu J, Shin Y, Kim K, Kim TI, Kim SW, **Cheon JH**., Bifidobacterium breve CBT BR3 is effective at relieving intestinal inflammation by augmenting goblet cell regeneration, *J Gastroenterol Hepatol.* 2023 Aug;38(8):1346-1354. doi: 10.1111/jgh.16209. Epub 2023 May 8. **(1st author)**
21. Park J, An H, Lim J, Park IS, Kim MH, Kim JH, Kim SW, Koh YI, Lee EY, **Cheon JH**., Interplay between chronic inflammation and clonal haematopoiesis of indeterminate potential in Behçet's disease, *Arthritis Res Ther.* 2023 Mar 2;25(1):33. doi: 10.1186/s13075-023-03014-w. **(1st author)**
22. Park J, **Cheon JH**, Lee KM, Kim YH, Ye BD, Eun CS, Kim SH, Lee SH, Lee JH, Schreiber S., Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab, *Gut Liver.* 2023 May 15;17(3):430-440. doi: 10.5009/gnl220005. Epub 2022 Aug 17. **(1st author)**
23. Park J, Chun J, Park SJ, Park JJ, Kim TI, Yoon H, **Cheon JH**., Effectiveness and tolerability of methotrexate monotherapy in Crohn's disease patients: a multicenter observational study, *Therap Adv Gastroenterol.* 2023 Aug 23;16:17562848231191664. doi: 10.1177/17562848231191664. eCollection 2023. **(1st author)**
24. Park J, Chun J, Yoon H, **Cheon JH**., Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study, *Inflamm Bowel Dis.* 2023 Apr 3;29(4):548-554. doi: 10.1093/ibd/izac105. **(1st author)**
25. Park J, Jeong GH, Song M, Yon DK, Lee SW, Koyanagi A, Jacob L, Kostev K, Dragioti E, Radua J, **Cheon JH**, Shin JI, Smith L., The global, regional, and national burden of inflammatory bowel diseases, 1990-2019: A systematic analysis for the global burden of disease study 2019, *Dig Liver Dis.* 2023 Oct;55(10):1352-1359. doi:

- 10.1016/j.dld.2023.04.003. Epub 2023 May 2. **(1st author)**
26. Park J, Park SJ, Park JJ, Kim TI, **Cheon JH.**, Long-term clinical outcomes of intestinal Behçet's disease: A 30-year cohort study at a tertiary hospital in South Korea, *J Gastroenterol Hepatol.* 2023 Mar;38(3):386-392. doi: 10.1111/jgh.16056. Epub 2022 Nov 21. **(1st author)**
 27. Seo SH, Cho KJ, Park HJ, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, **Cheon JH**, Yook JI, Kim MD, Joo DJ, Kim SU., Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/ β -catenin pathways in hepatocellular carcinoma, *Cell Commun Signal.* 2023 Nov 27;21(1):339. doi: 10.1186/s12964-023-01355-2. **(1st author)**
 28. Yoo EJ, Cho SH, Park SJ, Kim TI, Kim WH, **Cheon JH.**, Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease, *Yonsei Med J.* 2023 Sep;64(9):541-548. doi: 10.3349/ymj.2022.0588. **(1st author)**
 29. Yoon H, Park YS, Shin JE, Ye BD, Eun CS, Yoon SM, Cha JM, Kim YS, Huh KC, Park YS, **Cheon JH**, Jung ES, Kim Y, Jung SY., Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea, *BMC Gastroenterol.* 2023 Nov 21;23(1):405. doi: 10.1186/s12876-023-03008-7. **(1st author)**
 30. Yu J, Shin SJ, Park YJ, Kim HW, Lee BI, Ye BD, Kim GT, Kim SK, Kim JS, Kim YH, Jeong S, **Cheon JH.**, Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea, *BMC Gastroenterol.* 2023 Dec 19;23(1):449. doi: 10.1186/s12876-023-03090-x. **(1st author)**
 31. Ben-Horin S, Har-Noy O, Katsanos KH, Roblin X, Chen M, Gao X, Schwartz D, **Cheon JH**, Cesarini M, Bojic D, Protic M, Theodoropoulou A, Abu-Kaf H, Engel T, Tang J, Veyrard P, Lin X, Mao R, Christodoulou D, Karmiris K, Knezevic-Ivanovski T; ComboMesa investigators., Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial, *Clin Gastroenterol Hepatol.* 2022 Dec;20(12):2868-2875.e1. doi: 10.1016/j.cgh.2022.02.055. Epub 2022 Mar 8. **(1st author)**
 32. Cho KS, Kim S, Chun HB, **Cheon JH**, Cho MH, Lee AY, Arote RB., Efficient gene transfection to lung cancer cells via Folate-PEI-Sorbitol gene transporter, *PLoS One.* 2022 May 4;17(5):e0266181. doi: 10.1371/journal.pone.0266181. eCollection 2022. **(1st author)**
 33. Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group., Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study, *Lancet Gastroenterol Hepatol.* 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17. **(1st author)**
 34. Dignass AU, Paridaens K, Al Awadhi S, Begun J, **Cheon JH**, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Travis SPL., Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis, *Scand J Gastroenterol.* 2022 Apr;57(4):424-431. doi: 10.1080/00365521.2021.2015801. Epub 2021 Dec 21. **(1st author)**
 35. Hong SW, Ye BD, **Cheon JH**, Lee JH, Koo JS, Jang BI, Lee KM, Kim YS, Kim TO, Im JP, Song GA, Jung SA, Kim HS, Park DI, Kim HS, Huh KC, Kim YH, Cha JM, Seo GS, Choi CH, Song HJ, Baik GH, Kim JW, Shin SJ, Park YS, Lee CK, Lee J, Jung SH, Jung Y, Park SC, Joo YE, Jeon YT, Han DS, Yang SK, Kim HJ, Kim WH, Kim JS., Clinical Features and Long-term Prognosis of Crohn's Disease in Korea: Results from the Prospective CONNECT Study, *Gut Liver.* 2022 Nov 15;16(6):907-920. doi: 10.5009/gnl210299. Epub 2022 Mar 24. **(1st author)**
 36. Hyun HK, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, **Cheon JH.**, Radiology plus ileocolonoscopy versus radiology alone in Crohn's disease: prognosis prediction and mutual agreement, *Korean J Intern Med.* 2022 May;37(3):567-578. doi: 10.3904/kjim.2021.233. Epub 2021 Oct 26. **(1st author)**
 37. Hyun HK, Zhang HS, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, **Cheon JH.**, Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment, *BMC Gastroenterol.* 2022 Mar 27;22(1):143. doi: 10.1186/s12876-022-02225-w. **(1st author)**
 38. Hyun J, Lee SK, **Cheon JH**, Yong DE, Koh H, Kang YK, Kim MH, Sohn Y, Cho Y, Baek YJ, Kim JH, Ahn JY, Jeong SJ, Yeom JS, Choi JY., Faecal microbiota transplantation reduces amounts of antibiotic resistance genes in patients with multidrug-resistant organisms, *Antimicrob Resist Infect Control.* 2022 Jan 29;11(1):20. doi: 10.1186/s13756-022-01064-4. **(1st author)**
 39. Kang EA, **Cheon JH.**, Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease, *Gut Liver.* 2022 Jul 15;16(4):501-502. doi: 10.5009/gnl220186. **(corresponding author)**
 40. Kang J, Lee D, Lee KJ, Yoon JE, Kwon JH, Seo Y, Kim J, Chang SY, Park J, Kang EA, Park SJ, Park JJ, **Cheon JH**, Kim TI., Tumor-Suppressive Effect of Metformin via the Regulation of M2 Macrophages and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment of Colorectal Cancer, *Cancers (Basel).* 2022 Jun 10;14(12):2881. doi: 10.3390/cancers14122881. **(corresponding author)**
 41. Kim ER, Park JS, Kim JH, Oh JY, Oh IJ, Choi DH, Lee YS, Park IS, Kim S, Lee DH, **Cheon JH**, Bae JW, Lee M, Cho

- JW, An IB, Nam EJ, Yang SI, Lee MS, Bae SH, Lee YH., A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome, *Hepatology*. 2022 Jun;75(6):1523-1538. doi: 10.1002/hep.32235. Epub 2021 Dec 18. **(corresponding author)**
42. Kim JS, Geum MJ, Son ES, Yu YM, **Cheon JH**, Kwon KH., Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis, *Gut Liver*. 2022 Sep 15;16(5):736-745. doi: 10.5009/gnl210371. Epub 2022 Feb 11. **(corresponding author)**
 43. Kim Y, Kim JH, Kang EA, Park SJ, Park JJ, **Cheon JH**, Kim TI, Park J, Jeon SR., Rebleeding Rate and Risk Factors for Rebleeding after Device-Assisted Enteroscopy in Patients with Obscure Gastrointestinal Bleeding: A KASID Multicenter Study, *Diagnostics (Basel)*. 2022 Apr 11;12(4):954. doi: 10.3390/diagnostics12040954. **(corresponding author)**
 44. Kim YS, Na MJ, Ye BD, **Cheon JH**, Im JP, Kim JS; CONNECT Study Group., Clinical Characteristics of Korean Patients with Elderly-Onset Crohn's Disease: Results from the Prospective CONNECT Study, *Gut Liver*. 2022 Nov 15;16(6):995-1000. doi: 10.5009/gnl220350.
 45. Louis E, Paridaens K, Al Awadhi S, Begun J, **Cheon JH**, Dignass AU, Magro F, Márquez JR, Moschen AR, Narula N, Rydzewska G, Freddi MJ, Travis SP., Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis, *BMJ Open Gastroenterol*. 2022 Feb;9(1):e000853. doi: 10.1136/bmjgast-2021-000853. **(corresponding author)**
 46. Park HJ, Lee SW, Song JG, Van Kaer L, **Cheon JH**, Lim SJ, Han HK, Hong S., Aminoclay Nanoparticles Induce Anti-Inflammatory Dendritic Cells to Attenuate LPS-Elicited Pro-Inflammatory Immune Responses, *Molecules*. 2022 Dec 9;27(24):8743. doi: 10.3390/molecules27248743.
 47. Park J, **Cheon JH**., Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF- α , *Korean J Intern Med*. 2022 Sep;37(5):895-905. doi: 10.3904/kjim.2022.132. Epub 2022 Jul 27.
 48. Park JS, Park JW, Shin S, Lee ST, Shin SJ, Min BS, Park SJ, Park JJ, **Cheon JH**, Kim WH, Kim TI., Application of Multigene Panel Testing in Patients With High Risk for Hereditary Colorectal Cancer: A Descriptive Report Focused on Genotype-Phenotype Correlation, *Dis Colon Rectum*. 2022 Jun 1;65(6):793-803. doi: 10.1097/DCR.0000000000002039. Epub 2022 May 3.
 49. Park JW, Chang SY, Lim JS, Park SJ, Park JJ, **Cheon JH**, Kim WH, Kim TI., Impact of Visceral Fat on Survival and Metastasis of Stage III Colorectal Cancer, *Gut Liver*. 2022 Jan 15;16(1):53-61. doi: 10.5009/gnl20266. **(corresponding author)**
 50. Park JW, Seo MJ, Cho KS, Kook MC, Jeong JM, Roh SG, Cho SY, **Cheon JH**, Kim HK., Smad4 and p53 synergize in suppressing autochthonous intestinal cancer, *Cancer Med*. 2022 May;11(9):1925-1936. doi: 10.1002/cam4.4533. Epub 2022 Mar 11.
 51. Park YE, Moon HS, Yong D, Seo H, Yang J, Shin TS, Kim YK, Kim JR, Lee YN, Kim YH, Kim JS, **Cheon JH**., Microbial changes in stool, saliva, serum, and urine before and after anti-TNF- α therapy in patients with inflammatory bowel diseases, *Sci Rep*. 2022 Apr 15;12(1):6359. doi: 10.1038/s41598-022-10450-2. **(corresponding author)**
 52. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group., Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial, *Lancet Gastroenterol Hepatol*. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.
 53. Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbachner T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group., Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial, *Lancet*. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2.
 54. Son M, Park IS, Kim S, Ma HW, Kim JH, Kim TI, Kim WH, Han J, Kim SW, **Cheon JH**., Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function, *Front Immunol*. 2022 May 25;13:870817. doi: 10.3389/fimmu.2022.870817. eCollection 2022. **(corresponding author)**
 55. Yu J, **Cheon JH**., Microbial Modulation in Inflammatory Bowel Diseases, *Immune Netw*. 2022 Nov 29;22(6):e44. doi: 10.4110/in.2022.22.e44. eCollection 2022 Dec. **(corresponding author)**
 56. Yu J, Hyun HK, Park J, Kang EA, Park SJ, Park JJ, Kim TI, Kim WH, **Cheon JH**., Continued Postoperative Use of Tumor Necrosis Factor- α Inhibitors for the Prevention of Crohn's Disease Recurrence, *Gut Liver*. 2022 May 13;16(3):414-422. doi: 10.5009/gnl210062. **(corresponding author)**
 57. **Cheon JH**, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, Kim SH, Jung NH, Park JE, Lee YJ, Jeon DB, Lee YM, Kim JM, Park SH., Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness, *Adv Ther*. 2021 Aug;38(8):4366-4387. doi: 10.1007/s12325-021-01834-3. Epub 2021 Jul 12. **(1st author)**

58. **Cheon JH.**, Advances in Management of Intestinal Behçet's Disease: A Perspective From Gastroenterologists, *J Rheum Dis.* 2021 Jan 1;28(1):4-16. doi: 10.4078/jrd.2021.28.1.4.
59. Degenhardt F, Mayr G, Wendorff M, Boucher G, Ellinghaus E, Ellinghaus D, EIAbd H, Rosati E, Hübenenthal M, Juzenas S, Abedian S, Vahedi H, Thelma BK, Yang SK, Ye BD, **Cheon JH**, Datta LW, Daryani NE, Ellul P, Esaki M, Fuyuno Y, McGovern DPB, Haritunians T, Hong M, Juyal G, Jung ES, Kubo M, Kugathasan S, Lenz TL, Leslie S, Malekzadeh R, Midha V, Motyer A, Ng SC, Okou DT, Raychaudhuri S, Schembri J, Schreiber S, Song K, Sood A, Takahashi A, Torres EA, Umeno J, Alizadeh BZ, Weersma RK, Wong SH, Yamazaki K, Karlsen TH, Rioux JD, Brant SR; MAAIS Recruitment Center; Franke A; International IBD Genetics Consortium., Transethnic analysis of the human leukocyte antigen region for ulcerative colitis reveals not only shared but also ethnicity-specific disease associations, *Hum Mol Genet.* 2021 Apr 27;30(5):356-369. doi: 10.1093/hmg/ddab017.
60. Fremder M, Kim SW, Khamaysi A, Shimshilashvili L, Eini-Rider H, Park IS, Hadad U, **Cheon JH**, Ohana E., A transepithelial pathway delivers succinate to macrophages, thus perpetuating their pro-inflammatory metabolic state, *Cell Rep.* 2021 Aug 10;36(6):109521. doi: 10.1016/j.celrep.2021.109521. **(corresponding author)**
61. Jung YS, Han M, Park S, **Cheon JH.**, Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease, *Gut Liver.* 2021 Jan 15;15(1):92-99. doi: 10.5009/gnl19377.
62. Kang EA, Park JW, Park Y, Park SJ, Kim TI, Kim WH, Cho MS, **Cheon JH.**, C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet's disease, *BMC Gastroenterol.* 2021 Oct 7;21(1):362. doi: 10.1186/s12876-021-01922-2. **(corresponding author)**
63. Kim B, Chae J, Kim EH, Yang HI, **Cheon JH**, Kim TI, Kim WH, Jeon JY, Park SJ., Physical activity and quality of life of patients with inflammatory bowel disease, *Medicine (Baltimore).* 2021 Jul 9;100(27):e26290. doi: 10.1097/MD.00000000000026290.
64. Kim B, Seo Y, Kwon JH, Shin Y, Kim S, Park SJ, Park JJ, **Cheon JH**, Kim WH, Il Kim T., IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor, *Mol Carcinog.* 2021 Mar;60(3):188-200. doi: 10.1002/mc.23283. Epub 2021 Feb 5.
65. Kim DH, Park J, Kim S, Yoon MY, Ma HW, Park IS, Son M, Kim JH, Kim TI, Kim WH, Yoon SS, Kim SW, **Cheon JH.**, An Escherichia coli strain with extra catalase activity protects against murine colitis by scavenging hydrogen peroxide and regulating regulatory T cell/interleukin-17 pathways, *Free Radic Biol Med.* 2021 Oct;174:110-120. doi: 10.1016/j.freeradbiomed.2021.08.002. Epub 2021 Aug 4. **(corresponding author)**
66. Kim JM, Kang JG, Kim S, **Cheon JH.**, Deep-learning system for real-time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis, *J Gastroenterol Hepatol.* 2021 Aug;36(8):2141-2148. doi: 10.1111/jgh.15433. Epub 2021 Feb 20. **(corresponding author)**
67. Kim JM, Rim JH, Kim DH, Kim HY, Choi SK, Kim DY, Choi YJ, Yu S, **Cheon JH**, Gee HY., Microbiome analysis reveals that Ralstonia is responsible for decreased renal function in patients with ulcerative colitis, *Clin Transl Med.* 2021 Mar;11(3):e322. doi: 10.1002/ctm2.322. **(corresponding author)**
68. Kim MA, Kim YH, Chun J, Lee HS, Park SJ, **Cheon JH**, Kim TI, Kim WH, Park JJ., The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis, *J Crohns Colitis.* 2021 May 4;15(5):719-732. doi: 10.1093/ecco-jcc/jjaa225.
69. Kim YI, Yi EJ, Kim YD, Lee AR, Chung J, Ha HC, Cho JM, Kim SR, Ko HJ, **Cheon JH**, Hong YR, Chang SY., Local Stabilization of Hypoxia-Inducible Factor-1 α Controls Intestinal Inflammation via Enhanced Gut Barrier Function and Immune Regulation, *Front Immunol.* 2021 Jan 14;11:609689. doi: 10.3389/fimmu.2020.609689. eCollection 2020.
70. Lee YI, Park Y, Park SJ, Kim TI, Kim WH, **Cheon JH.**, Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis, *Gut Liver.* 2021 Mar 15;15(2):232-242. doi: 10.5009/gnl19433. **(corresponding author)**
71. Moon JR, Lee CK, Hong SN, Im JP, Ye BD, Cha JM, Jung SA, Lee KM, Park DI, Jeon YT, Park YS, **Cheon JH**, Kim H, Seo B, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID)., Corrigendum: Unmet Psychosocial Needs of Patients Newly Diagnosed with Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea, *Gut Liver.* 2021 Jan 15;15(1):146-147. doi: 10.5009/gnl15011.
72. Park IS, Son M, Ma HW, Kim J, Kim DH, Kim SW, **Cheon JH.**, Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice, *Intest Res.* 2021 Jul;19(3):349-353. doi: 10.5217/ir.2020.00075. Epub 2020 Nov 2. **(corresponding author)**
73. Park J, **Cheon JH.**, Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?, *Gut Liver.* 2021 Sep 15;15(5):641-642. doi: 10.5009/gnl210345. **(corresponding author)**
74. Park J, **Cheon JH.**, Incidence and Prevalence of Inflammatory Bowel Disease across Asia, *Yonsei Med J.* 2021 Feb;62(2):99-108. doi: 10.3349/ymj.2021.62.2.99. **(corresponding author)**
75. Park J, Jeong D, Chung YW, Han S, Kim DH, Yu J, **Cheon JH**, Ryu JH., Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet's disease from Crohn's disease, *Sci Rep.* 2021 May 26;11(1):11019. doi: 10.1038/s41598-021-90250-2. **(corresponding author)**
76. Park J, Kim DH, Kim S, Ma HW, Park IS, Son M, Kim JH, Shin Y, Kim SW, **Cheon JH.**, Anti-inflammatory properties of

- Escherichia coli Nissle 1917 in a murine colitis model, *Intest Res.* 2021 Oct;19(4):478-481. doi: 10.5217/ir.2021.00121. Epub 2021 Oct 26.
77. Park J, Park S, Lee SA, Park SJ, **Cheon JH.**, Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management, *Korean J Intern Med.* 2021 Sep;36(5):1040-1048. doi: 10.3904/kjim.2021.114. Epub 2021 Aug 5. **(corresponding author)**
 78. Park JJ, Kim BC, Hong SP, Seo Y, Lee HS, Park YS, Na SY, Park SC, Park J, Kim JH, Moon CM, Huh KC, Park SJ, **Cheon JH.**, Kim WH, Kim TI., The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis, *Cancer Prev Res (Phila).* 2021 May;14(5):563-572. doi: 10.1158/1940-6207.CAPR-20-0580. Epub 2021 Jan 28.
 79. Park JW, Jeong JM, Cho KS, Cho SY, **Cheon JH.**, Choi DH, Park SJ, Kim HK., MiR-30a and miR-200c differentiate cholangiocarcinomas from gastrointestinal cancer liver metastases, *PLoS One.* 2021 Apr 14;16(4):e0250083. doi: 10.1371/journal.pone.0250083. eCollection 2021.
 80. Park YE, Park SJ, Park JJ, **Cheon JH.**, Kim T, Kim WH., Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet's disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin, *BMC Gastroenterol.* 2021 Jan 21;21(1):32. doi: 10.1186/s12876-021-01609-8.
 81. Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group., Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis, *N Engl J Med.* 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
 82. Seo DH, Che X, Kim S, Kim DH, Ma HW, Kim JH, Kim TI, Kim WH, Kim SW, **Cheon JH.**, Triggering Receptor Expressed on Myeloid Cells-1 Agonist Regulates Intestinal Inflammation via Cd177(+) Neutrophils, *Front Immunol.* 2021 Mar 9;12:650864. doi: 10.3389/fimmu.2021.650864. eCollection 2021. **(corresponding author)**
 83. Yazici Y, Hatemi G, Bodaghi B, **Cheon JH.**, Suzuki N, Ambrose N, Yazici H., Behçet syndrome, *Nat Rev Dis Primers.* 2021 Sep 16;7(1):67. doi: 10.1038/s41572-021-00301-1. **(corresponding author)**
 84. Ye BD, **Cheon JH.**, Song KH, Kim JS, Kim YH, Yoon H, Lee KM, Kang SB, Jang BI, Park JJ, Kim TO, Lee DW, Foo CY, Shin JE, Park DI., The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study, *Therap Adv Gastroenterol.* 2021 Jul 5;14:17562848211024769. doi: 10.1177/17562848211024769. eCollection 2021. **(corresponding author)**
 85. Yoon JY, Cha JM, Lee CK, Park YS, Huh KC, Shin JE, Kim YS, Eun CS, Yoon SM, **Cheon JH.**, Park YS, Ye BD, Lee Y, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID)., Early course of newly diagnosed moderate-to-severe ulcerative colitis in Korea: Results from a hospital-based inception cohort study (MOSAIK), *J Gastroenterol Hepatol.* 2021 Aug;36(8):2149-2156. doi: 10.1111/jgh.15435. Epub 2021 Feb 20.
 86. Yu J, Park J, Kang EA, Park SJ, Park JJ, Kim TI, Kim WH, **Cheon JH.**, Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis, *Gut Liver.* 2021 Nov 15;15(6):858-866. doi: 10.5009/gnl20294. **(corresponding author)**
 87. Chang JY, Kim JH, Kang J, Park Y, Park SJ, **Cheon JH.**, Kim WH, Kim H, Park JJ, Kim TI., mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer, *Yonsei Med J.* 2020 Jul;61(7):572-578. doi: 10.3349/ymj.2020.61.7.572.
 88. Chang JY, Park SJ, Jung ES, Jung SA, Moon CM, Chun J, Park JJ, Kim ES, Park Y, Kim TI, Kim WH, **Cheon JH.**, Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases, *Clin Gastroenterol Hepatol.* 2020 Aug;18(9):2010-2018.e2. doi: 10.1016/j.cgh.2019.08.034. Epub 2019 Aug 22. **(corresponding author)**
 89. Han M, Jung YS, **Cheon JH.**, Park S., Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study, *Yonsei Med J.* 2020 May;61(5):382-390. doi: 10.3349/ymj.2020.61.5.382. **(corresponding author)**
 90. Han M, Jung YS, **Cheon JH.**, Park S., Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study, *Yonsei Med J.* 2020 Jan;61(1):48-55. doi: 10.3349/ymj.2020.61.1.48. **(corresponding author)**
 91. Jeong SH, Choi JS, Kim JW, Kim HM, Kim HS, Im JP, Kim JS, Kim YS, **Cheon JH.**, Kim WH, Ye BD, Kim YH, Han DS., Clinical Features of Intra-Abdominal Abscess and Intestinal Free-Wall Perforation in Korean Patients with Crohn's Disease: Results from the CONNECT Study, *J Clin Med.* 2020 Dec 31;10(1):116. doi: 10.3390/jcm10010116.
 92. Jung YS, Han M, Park S, **Cheon JH.**, Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study, *Korean J Intern Med.* 2020 Sep;35(5):1104-1113. doi: 10.3904/kjim.2020.001. Epub 2020 Apr 21.
 93. Jung YS, Han M, Park S, **Cheon JH.**, Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study, *Dig Dis Sci.* 2020 May;65(5):1436-1444. doi: 10.1007/s10620-019-05867-1. Epub 2019 Nov 1. **(corresponding author) (1st author)**
 94. Kim DH, Kim S, Ahn JB, Kim JH, Ma HW, Seo DH, Che X, Park KC, Jeon JY, Kim SY, Lee HC, Lee JY, Kim TI, Kim

- WH, Kim SW, **Cheon JH.**, Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice, *Int J Med Microbiol.* 2020 Feb;310(2):151391. doi: 10.1016/j.ijmm.2020.151391. Epub 2020 Jan 7. **(corresponding author) (1st author)**
95. Kim HM, Kim JW, Kim HS, Kim JS, Kim YS, **Cheon JH.**, Kim WH, Ye BD, Moon W, Jung SH, Kim YH, Han DS., Effect of Thiopurine on Potential Surgical Intervention in Crohn's Disease in Korea: Results from the CONNECT Study, *J Clin Med.* 2020 Dec 23;10(1):25. doi: 10.3390/jcm10010025. **(corresponding author) (1st author)**
 96. Kim HY, **Cheon JH.**, Lee SH, Min JY, Back SY, Song JG, Kim DH, Lim SJ, Han HK., Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization, *J Nanobiotechnology.* 2020 Jan 21;18(1):17. doi: 10.1186/s12951-020-0579-7. **(1st author)**
 97. Kim J, Im JP, Yim JJ, Lee CK, Park DI, Eun CS, Jung SA, Shin JE, Lee KM, **Cheon JH.**, Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy, *Korean J Gastroenterol.* 2020 Jan 25;75(1):29-38. doi: 10.4166/kjg.2020.75.1.29.
 98. Kim JH, Ahn JB, Kim DH, Kim S, Ma HW, Che X, Seo DH, Kim TI, Kim WH, **Cheon JH.**, Kim SW., Glutathione S-transferase theta 1 protects against colitis through goblet cell differentiation via interleukin-22, *FASEB J.* 2020 Feb;34(2):3289-3304. doi: 10.1096/fj.201902421R. Epub 2020 Jan 9. **(corresponding author)**
 99. Kim JM, **Cheon JH.**, Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases, *Intest Res.* 2020 Jul;18(3):249-264. doi: 10.5217/ir.2019.00128. Epub 2020 Apr 18. (co-1st author)
 100. Kim JM, Kim DH, Park HJ, Ma HW, Park IS, Son M, Ro SY, Hong S, Han HK, Lim SJ, Kim SW, **Cheon JH.**, Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model, *J Nanobiotechnology.* 2020 Sep 15;18(1):133. doi: 10.1186/s12951-020-00693-4. **(corresponding author)**
 101. Kim JM, Park JW, Lee JH, Park YH, Park SJ, **Cheon JH.**, Kim WH, Kim TI., Survival Benefit for Metformin Through Better Tumor Response by Neoadjuvant Concurrent Chemoradiotherapy in Rectal Cancer, *Dis Colon Rectum.* 2020 Jun;63(6):758-768. doi: 10.1097/DCR.0000000000001624.
 102. Kim SB, **Cheon JH.**, Park JJ, Kim ES, Jeon SW, Jung SA, Park DI, Lee CK, Im JP, Kim YS, Kim HS, Lee J, Eun CS, Lee JM, Jang BI, Seo GS., Risk Factors for Postoperative Recurrence in Korean Patients with Crohn's Disease, *Gut Liver.* 2020 May 15;14(3):331-337. doi: 10.5009/gnl19085. **(corresponding author)**
 103. Kim SW, Kim S, Son M, **Cheon JH.**, Park YS., Melatonin controls microbiota in colitis by goblet cell differentiation and antimicrobial peptide production through Toll-like receptor 4 signalling, *Sci Rep.* 2020 Feb 10;10(1):2232. doi: 10.1038/s41598-020-59314-7. **(corresponding author)**
 104. Moon JR, Lee CK, Hong SN, Im JP, Ye BD, Cha JM, Jung SA, Lee KM, Park DI, Jeon YT, Park YS, **Cheon JH.**, Kim H, Seo B, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for Study of Intestinal Diseases., Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea, *Gut Liver.* 2020 Jul 15;14(4):459-467. doi: 10.5009/gnl19107.
 105. Park J, Jeong D, Chung YW, Kim DH, **Cheon JH.**, Ryu JH., Quantitative Proteomic Analysis of the Expression of SARS-CoV-2 Receptors in the Gut of Patients with Chronic Enterocolitis, *Yonsei Med J.* 2020 Oct;61(10):891-894. doi: 10.3349/ymj.2020.61.10.891. **(corresponding author)**
 106. Park Y, **Cheon JH.**, Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents, *Curr Gastroenterol Rep.* 2020 Mar 19;22(5):24. doi: 10.1007/s11894-020-00759-1.
 107. Park YE, Park Y, Park SJ, Kim TI, Kim WH, Kim JN, Lee NR, **Cheon JH.**, Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?, *Intest Res.* 2020 Jan;18(1):85-95. doi: 10.5217/ir.2019.00055. Epub 2019 Jul 19. **(corresponding author)**
 108. Saruta M, Park DI, Kim YH, Yang SK, Jang BI, **Cheon JH.**, Im JP, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick KJ, Cataldi F, Watanabe M, Hibi T., Anti-MAAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study, *Intest Res.* 2020 Jan;18(1):45-55. doi: 10.5217/ir.2019.00039. Epub 2020 Jan 30.
 109. Seo Y, Kim J, Park SJ, Park JJ, **Cheon JH.**, Kim WH, Kim TI., Metformin Suppresses Cancer Stem Cells through AMPK Activation and Inhibition of Protein Prenylation of the Mevalonate Pathway in Colorectal Cancer, *Cancers (Basel).* 2020 Sep 8;12(9):2554. doi: 10.3390/cancers12092554.
 110. Seong H, Lee SK, **Cheon JH.**, Yong DE, Koh H, Kang YK, Jeong WY, Lee WJ, Sohn Y, Cho Y, Hyun JH, Baek YJ, Kim MH, Kim JH, Ahn JY, Ku NS, Jeong SJ, Yeom JS, Cho MS, Lee JH, Kim BY, Choi JY., Fecal Microbiota Transplantation for multidrug-resistant organism: Efficacy and Response prediction, *J Infect.* 2020 Nov;81(5):719-725. doi: 10.1016/j.jinf.2020.09.003. Epub 2020 Sep 11.
 111. Suh JH, Park MC, Goughnour PC, Min BS, Kim SB, Lee WY, Cho YB, **Cheon JH.**, Lee KY, Nam DH, Kim S., Plasma Lysyl-tRNA Synthetase 1 (KARS1) as a Novel Diagnostic and Monitoring Biomarker for Colorectal Cancer, *J Clin Med.* 2020 Feb 15;9(2):533. doi: 10.3390/jcm9020533. **(corresponding author)**
 112. Cha JH, Jung DH, Kim JH, Youn YH, Park H, Park JJ, Um YJ, Park SJ, **Cheon JH.**, Kim TI, Kim WH, Lee HJ., Long-term outcomes according to additional treatments after endoscopic resection for rectal small neuroendocrine tumors, *Sci Rep.* 2019 Mar 20;9(1):4911. doi: 10.1038/s41598-019-40668-6. **(corresponding author)**

113. Chang JY, **Cheon JH.**, Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics, *Dig Dis Sci.* 2019 Sep;64(9):2395-2403. doi: 10.1007/s10620-019-05720-5. Epub 2019 Jul 9. **(corresponding author)**
114. Cho MS, Kim H, Han YD, Hur H, Min BS, Baik SH, **Cheon JH.**, Lim JS, Lee KY, Kim NK., Endoscopy and magnetic resonance imaging-based prediction of ypT stage in patients with rectal cancer who received chemoradiotherapy: Results from a prospective study of 110 patients, *Medicine (Baltimore).* 2019 Aug;98(35):e16614. doi: 10.1097/MD.00000000000016614. **(corresponding author)**
115. Degenhardt F, Wendorff M, Wittig M, Ellinghaus E, Datta LW, Schembri J, Ng SC, Rosati E, Hübenthal M, Ellinghaus D, Jung ES, Lieb W, Abedian S, Malekzadeh R, **Cheon JH.**, Ellul P, Sood A, Midha V, Thelma BK, Wong SH, Schreiber S, Yamazaki K, Kubo M, Boucher G, Rioux JD, Lenz TL, Brant SR, Franke A., Construction and benchmarking of a multi-ethnic reference panel for the imputation of HLA class I and II alleles, *Hum Mol Genet.* 2019 Jun 15;28(12):2078-2092. doi: 10.1093/hmg/ddy443. **(corresponding author)**
116. Han M, Jung YS, **Cheon JH.**, Park S., Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases, *J Gastroenterol Hepatol.* 2019 Jul;34(7):1166-1174. doi: 10.1111/jgh.14609. Epub 2019 Feb 10. **(corresponding author)**
117. Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, **Cheon JH.**, ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases, *J Gastroenterol Hepatol.* 2019 Oct;34(10):1727-1735. doi: 10.1111/jgh.14652. Epub 2019 Apr 1. **(corresponding author)**
118. Kim DH, Kim S, Lee JH, Kim JH, Che X, Ma HW, Seo DH, Kim TI, Kim WH, Kim SW, **Cheon JH.**, *Lactobacillus acidophilus* suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress, *J Gastroenterol Hepatol.* 2019 Jan;34(1):178-185. doi: 10.1111/jgh.14362. Epub 2018 Jul 10. **(corresponding author)**
119. Lee DH, Han JY, Park JJ, **Cheon JH.**, Kim M., Ophthalmologic Manifestation of Inflammatory Bowel Disease: A Review, *Korean J Gastroenterol.* 2019 May 25;73(5):269-275. doi: 10.4166/kjg.2019.73.5.269.
120. Lee HJ, Kim JH, Hong S, Hwang I, Park SJ, Kim TI, Kim WH, Yu JW, Kim SW, **Cheon JH.**, Proteomics-based functional studies reveal that galectin-3 plays a protective role in the pathogenesis of intestinal Behçet's disease, *Sci Rep.* 2019 Aug 12;9(1):11716. doi: 10.1038/s41598-019-48291-1.
121. Lee HJ, Park SJ, **Cheon JH.**, Kim TI, Kim WH, Kim HJ., The relationship between diverticulosis and colorectal neoplasia: A meta-analysis, *PLoS One.* 2019 May 29;14(5):e0216380. doi: 10.1371/journal.pone.0216380. eCollection 2019. **(corresponding author)**
122. Park JS, Kang B, Park Y, Park SJ, **Cheon JH.**, Jung M, Beom SH, Shin SJ, Hur H, Min BS, Baik SH, Lee KY, Ahn JB, Kim NK, Kim TI., Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors, *J Cancer Prev.* 2019 Mar;24(1):48-53. doi: 10.15430/JCP.2019.24.1.48. Epub 2019 Mar 30.
123. Park Y, Park SJ, **Cheon JH.**, Kim WH, Kim TI., Association of Family History With Cancer Recurrence, Survival, and the Incidence of Colorectal Adenoma in Patients With Colorectal Cancer, *J Cancer Prev.* 2019 Mar;24(1):1-10. doi: 10.15430/JCP.2019.24.1.1. Epub 2019 Mar 30. **(corresponding author)**
124. Park YE, Park Y, Park SJ, **Cheon JH.**, Kim WH, Kim TI., Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration, *Surg Endosc.* 2019 Apr;33(4):1225-1234. doi: 10.1007/s00464-018-6399-2. Epub 2018 Aug 27. **(corresponding author)**
125. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group., Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis, *N Engl J Med.* 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. **(corresponding author)**
126. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group., Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis, *N Engl J Med.* 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750. **(corresponding author)**
127. Yang DH, Park SJ, Kim HS, Park YS, Park DI, Lee KM, Jung SA, Choi CH, Koo JS, **Cheon JH.**, Yang SK, Kim WH, Kim J, Kim H, Ryan Choi CH; Korean Association for the Study of the Intestinal Diseases (KASID) study., High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial, *Am J Gastroenterol.* 2019 Oct;114(10):1642-1648. doi: 10.14309/ajg.0000000000000341. **(corresponding author)**
128. Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, Fishman S, Levchenko O, **Cheon JH.**, Scribano ML, Mateescu RB, Lee KM, Eun CS, Lee SJ, Lee SY, Kim H, Schreiber S, Fowler H, Cheung R, Kim YH., Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study, *Lancet.* 2019 Apr 27;393(10182):1699-1707. doi: 10.1016/S0140-6736(18)32196-2. Epub 2019 Mar 28.
129. Chang JY, **Cheon JH.**, Park Y, Park SJ, Kim TI, Kim WH., Does Medical Acceleration Improve Outcomes in Ulcerative

- Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?, *Dig Dis Sci*. 2018 Nov;63(11):3041-3048. doi: 10.1007/s10620-018-5193-2. Epub 2018 Jul 9. **(corresponding author)**
130. Chang JY, **Cheon JH**., Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis, *Gut Liver*. 2018 Mar 15;12(2):117-118. doi: 10.5009/gnl17445. **(corresponding author)**
 131. Che X, Park KC, Park SJ, Kang YH, Jin HA, Kim JW, Seo DH, Kim DK, Kim TI, Kim WH, Kim SW, **Cheon JH**., Protective effects of guggulsterone against colitis are associated with the suppression of TREM-1 and modulation of macrophages, *Am J Physiol Gastrointest Liver Physiol*. 2018 Jul 1;315(1):G128-G139. doi: 10.1152/ajpgi.00027.2018. Epub 2018 Mar 15.
 132. Chun J, Im JP, Kim JW, Lee KL, Choi CH, Kim H, **Cheon JH**, Ye BD, Kim YH, Kim YS, Jeon YT, Han DS, Kim WH, Kim JS., Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study, *Gut Liver*. 2018 Sep 15;12(5):544-554. doi: 10.5009/gnl18157.
 133. Han M, Jung YS, Kim WH, **Cheon JH**, Park S., Cancer Risk in Patients with Intestinal Behçet's Disease: A Nationwide Population-Based Study, *Gut Liver*. 2018 Jul 15;12(4):433-439. doi: 10.5009/gnl17324.
 134. Jo JH, Park SJ, **Cheon JH**, Kim TI, Kim WH., Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease, *J Gastroenterol Hepatol*. 2018 Feb;33(2):375-379. doi: 10.1111/jgh.13855.
 135. Jung ES, Petersen BS, Mayr G, **Cheon JH**, Kang Y, Lee SJ, Che X, Kim WH, Kim S, Schreiber S, Franke A, Koh H., Compound heterozygous mutations in IL10RA combined with a complement factor properdin mutation in infantile-onset inflammatory bowel disease, *Eur J Gastroenterol Hepatol*. 2018 Dec;30(12):1491-1496. doi: 10.1097/MEG.0000000000001247.
 136. Kim JH, Lee KJ, Seo Y, Kwon JH, Yoon JP, Kang JY, Lee HJ, Park SJ, Hong SP, **Cheon JH**, Kim WH, Il Kim T., Publisher Correction: Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism, *Sci Rep*. 2018 Aug 28;8(1):13111. doi: 10.1038/s41598-018-29895-5.
 137. Kim JH, Lee KJ, Seo Y, Kwon JH, Yoon JP, Kang JY, Lee HJ, Park SJ, Hong SP, **Cheon JH**, Kim WH, Il Kim T., Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism, *Sci Rep*. 2018 Jan 11;8(1):409. doi: 10.1038/s41598-017-18762-4.
 138. Kim OZ, Han DS, Park CH, Eun CS, Kim YS, Kim YH, **Cheon JH**, Ye BD, Kim JS., The Clinical Characteristics and Prognosis of Crohn's Disease in Korean Patients Showing Proximal Small Bowel Involvement: Results from the CONNECT Study, *Gut Liver*. 2018 Jan 15;12(1):67-72. doi: 10.5009/gnl16500.
 139. Kwak MS, Kim KJ, **Cheon JH**, Kim WS, Lee JM, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK., Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease, *Gastroenterol Res Pract*. 2018 Jan 18;2018:4826973. doi: 10.1155/2018/4826973. eCollection 2018. **(corresponding author)**
 140. Lee HJ, Hong SP, **Cheon JH**, Kim TI, Kim WH, Park SJ., Clinical Outcomes of Self-Expandable Metal Stents for Malignant Rectal Obstruction, *Dis Colon Rectum*. 2018 Jan;61(1):43-50. doi: 10.1097/DCR.0000000000000910.
 141. Lee HS, Kim SB, Lee HJ, Park SJ, Hong SP, **Cheon JH**, Kim WH, Kim TI., Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer, *Gastrointest Endosc*. 2018 Mar;87(3):688-694.e2. doi: 10.1016/j.gie.2017.04.004. Epub 2017 Apr 18.
 142. Lee HW, Park SJ, Jeon SR, Ye BD, Park JJ, **Cheon JH**, Kim TI, Kim WH; Korean Association for the Study of the Intestinal Diseases (KASID)., Long-Term Outcomes of Endoscopic Balloon Dilation for Benign Strictures in Patients with Inflammatory Bowel Disease, *Gut Liver*. 2018 Sep 15;12(5):530-536. doi: 10.5009/gnl17396.
 143. Lee JH, Park YE, Seo N, Lee HJ, Park SJ, Kim TI, Kim WH, Lim JS, **Cheon JH**., Magnetic resonance enterography predicts the prognosis of Crohn's disease, *Intest Res*. 2018 Jul;16(3):445-457. doi: 10.5217/ir.2018.16.3.445. Epub 2018 Jul 27.
 144. Lee JM, Lee KM, Kim JS, Kim YS, **Cheon JH**, Ye BD, Kim YH, Han DS, Lee CK, Park HJ., Postoperative course of Crohn disease according to timing of bowel resection: Results from the CONNECT Study, *Medicine (Baltimore)*. 2018 Apr;97(16):e0459. doi: 10.1097/MD.00000000000010459.
 145. Lee SW, Park HJ, **Cheon JH**, Wu L, Van Kaer L, Hong S., iNKT Cells Suppress Pathogenic NK1.1(+)CD8(+) T Cells in DSS-Induced Colitis, *Front Immunol*. 2018 Oct 2;9:2168. doi: 10.3389/fimmu.2018.02168. eCollection 2018.
 146. Lee YJ, Yoon JY, Park JJ, Park SJ, Kim JH, Youn YH, Kim TI, Park H, Kim WH, **Cheon JH**., Clinical outcomes and factors related to colonic perforations in patients receiving self-expandable metal stent insertion for malignant colorectal obstruction, *Gastrointest Endosc*. 2018 Jun;87(6):1548-1557.e1. doi: 10.1016/j.gie.2018.02.006. Epub 2018 Feb 13.
 147. Moon CM, Kim SW, Ahn JB, Ma HW, Che X, Kim TI, Kim WH, **Cheon JH**., Deep Resequencing of Ulcerative Colitis-Associated Genes Identifies Novel Variants in Candidate Genes in the Korean Population, *Inflamm Bowel Dis*. 2018 Jul 12;24(8):1706-1717. doi: 10.1093/ibd/izy122. **(corresponding author)**
 148. Park J, **Cheon JH**, Park Y, Park SJ, Kim TI, Kim WH., Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience, *Intest Res*. 2018 Apr;16(2):315-318. doi:

- 10.5217/ir.2018.16.2.315. Epub 2018 Apr 30. **(corresponding author)**
149. Park J, **Cheon JH.**, Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease, Gut Liver. 2018 Nov 15;12(6):623-632. doi: 10.5009/gnl17462.
 150. Park J, Kim JH, Park Y, Park SJ, **Cheon JH.**, Kim WH, Park JS, Jeon JY, Kim TI., Resting heart rate is an independent predictor of advanced colorectal adenoma recurrence, PLoS One. 2018 Mar 2;13(3):e0193753. doi: 10.1371/journal.pone.0193753. eCollection 2018. **(corresponding author)**
 151. Park J, Lee HJ, Park SJ, Hur H, Min BS, **Cheon JH.**, Kim TI, Kim NK, Kim WH., Long-term outcomes after stenting as a bridge to surgery in patients with obstructing left-sided colorectal cancer, Int J Colorectal Dis. 2018 Jun;33(6):799-807. doi: 10.1007/s00384-018-3009-7. Epub 2018 Mar 12. **(corresponding author)**
 152. Park JJ, Rhee K, Yoon JY, Park SJ, Kim JH, Kim JH, Youn YH, Kim TI, Park H, Kim WH, **Cheon JH.**, Impact of peritoneal carcinomatosis on clinical outcomes of patients receiving self-expandable metal stents for malignant colorectal obstruction, Endoscopy. 2018 Dec;50(12):1163-1174. doi: 10.1055/a-0657-3764. Epub 2018 Aug 31. **(corresponding author)**
 153. Park JW, Kim TI, **Cheon JH.**, Probe-based confocal laser endomicroscopy in the differential diagnosis of inflammatory bowel diseases: a case series, Intest Res. 2018 Oct;16(4):641-645. doi: 10.5217/ir.2018.00035. Epub 2018 Oct 10. **(corresponding author)**
 154. Park JW, Park Y, Park SJ, Kim TI, Kim WH, **Cheon JH.**, Development of a Novel Endoscopic Scoring System to Predict Relapse after Surgery in Intestinal Behçet's Disease, Gut Liver. 2018 Nov 15;12(6):674-681. doi: 10.5009/gnl17547.
 155. Park YE, **Cheon JH.**, Park JJ, Kim YJ, Choi CH, Park Y, Park SJ, Kim TI, Kim WH., Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study, Int J Colorectal Dis. 2018 Oct;33(10):1497-1500. doi: 10.1007/s00384-018-3123-6. Epub 2018 Jul 9. **(corresponding author)**
 156. Park YE, **Cheon JH.**, Park Y, Park SJ, Kim TI, Kim WH., The outcomes and risk factors of early readmission in patients with intestinal Behçet's disease, Clin Rheumatol. 2018 Jul;37(7):1913-1920. doi: 10.1007/s10067-017-3904-2. Epub 2017 Nov 7. **(corresponding author)**
 157. Park YE, **Cheon JH.**, Updated treatment strategies for intestinal Behçet's disease, Korean J Intern Med. 2018 Jan;33(1):1-19. doi: 10.3904/kjim.2017.377. Epub 2017 Dec 8. **(corresponding author)**
 158. Shin DS, **Cheon JH.**, Park YE, Park Y, Park SJ, Kim TI, Kim WH., Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis, Dig Dis Sci. 2018 Nov;63(11):3097-3104. doi: 10.1007/s10620-018-5218-x. Epub 2018 Aug 25.
 159. Yoon JY, **Cheon JH.**, Park SJ, Kim TI, Kim WH., Effects of Perianal Involvement on Clinical Outcomes in Crohn's Disease over 10 Years, Gut Liver. 2018 May 15;12(3):297-305. doi: 10.5009/gnl17275.
 160. Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, **Cheon JH.**, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN., Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice, World J Gastroenterol. 2017 Apr 28;23(16):2995-3002. doi: 10.3748/wjg.v23.i16.2995. **(corresponding author)**
 161. **Cheon JH.**, Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease, J Gastroenterol Hepatol. 2017 Apr;32(4):769-777. doi: 10.1111/jgh.13612. **(corresponding author)**
 162. Chi JH, Seo GS, **Cheon JH.**, Lee SH., Isoliquiritigenin inhibits TNF- α -induced release of high-mobility group box 1 through activation of HDAC in human intestinal epithelial HT-29 cells, Eur J Pharmacol. 2017 Feb 5;796:101-109. doi: 10.1016/j.ejphar.2016.12.026. Epub 2016 Dec 21. **(corresponding author)**
 163. Han M, Jung YS, Kim WH, **Cheon JH.**, Park S., Incidence and clinical outcomes of intestinal Behçet's disease in Korea, 2011-2014: a nationwide population-based study, J Gastroenterol. 2017 Aug;52(8):920-928. doi: 10.1007/s00535-016-1300-3. Epub 2016 Dec 27. **(corresponding author)**
 164. Han MS, Lee HJ, Park SJ, Hong SP, **Cheon JH.**, Kim WH, Kim TI., The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma, Int J Colorectal Dis. 2017 Aug;32(8):1223-1226. doi: 10.1007/s00384-017-2782-z. Epub 2017 Feb 16.
 165. Hwang SW, Kim JH, Im JP, Ye BD, Koo HS, Huh KC, **Cheon JH.**, Kim YS, Kim YH, Han DS, Kim WH, Kim JS; Crohn's disease clinical network and cohort (CONNECT) study., Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: Results from the CONNECT study, J Gastroenterol Hepatol. 2017 Oct;32(10):1716-1722. doi: 10.1111/jgh.13775. (Co-1st Author)
 166. Jung ES, Park HJ, Kong KA, Choi JH, **Cheon JH.**, Association study between OCTN1 functional haplotypes and Crohn's disease in a Korean population, Korean J Physiol Pharmacol. 2017 Jan;21(1):11-17. doi: 10.4196/kjpp.2017.21.1.11. Epub 2016 Dec 21.
 167. Jung YS, Han M, Kim DY, **Cheon JH.**, Park S., Cancer risk in Korean patients with Behçet's disease: A nationwide population-based study, PLoS One. 2017 Dec 29;12(12):e0190182. doi: 10.1371/journal.pone.0190182. eCollection 2017. **(corresponding author)**

168. Jung YS, Han M, Kim WH, Park S, **Cheon JH.**, Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study, *Dig Dis Sci.* 2017 Aug;62(8):2102-2112. doi: 10.1007/s10620-017-4640-9. Epub 2017 Jun 7. **(corresponding author)**
169. Jung YS, Han M, Park S, Kim WH, **Cheon JH.**, Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study, *J Crohns Colitis.* 2017 Aug 1;11(8):954-962. doi: 10.1093/ecco-jcc/jjx040. **(corresponding author)**
170. Kim B, Kim YH, Park SJ, **Cheon JH.**, Kim TI, Kim WH, Kim H, Hong SP., Probe-based confocal laser endomicroscopy for evaluating the submucosal invasion of colorectal neoplasms, *Surg Endosc.* 2017 Feb;31(2):594-601. doi: 10.1007/s00464-016-5003-x. Epub 2016 Jun 20.
171. Kim DH, **Cheon JH.**, Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies, *Immune Netw.* 2017 Feb;17(1):25-40. doi: 10.4110/in.2017.17.1.25. Epub 2017 Feb 23. **(corresponding author)**
172. Kim DH, Park Y, Kim B, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet's disease, *J Gastroenterol Hepatol.* 2017 Mar;32(3):595-601. doi: 10.1111/jgh.13530.
173. Kim HS, **Cheon JH.**, Jung ES, Park J, Aum S, Park SJ, Eun S, Lee J, Rütther U, Yeo GSH, Ma M, Park KS, Naito T, Kakuta Y, Lee JH, Kim WH, Lee MG., A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD, *Gut.* 2017 Nov;66(11):1926-1935. doi: 10.1136/gutjnl-2016-311921. Epub 2016 Aug 24.
174. Kim SB, Lee HJ, Park SJ, Hong SP, **Cheon JH.**, Kim WH, Kim TI., Comparison of Colonoscopy Surveillance Outcomes Between Young and Older Colorectal Cancer Patients, *J Cancer Prev.* 2017 Sep;22(3):159-165. doi: 10.15430/JCP.2017.22.3.159. Epub 2017 Sep 30. **(corresponding author)**
175. Kim SW, Jung YS, Ahn JB, Shin ES, Jang HW, Lee HJ, Il Kim T, Kim DY, Bang D, Kim WH, **Cheon JH.**, Identification of genetic susceptibility loci for intestinal Behçet's disease, *Sci Rep.* 2017 Jan 3;7:39850. doi: 10.1038/srep39850.
176. Lee HJ, **Cheon JH.**, Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease, *Intest Res.* 2017 Jul;15(3):311-317. doi: 10.5217/ir.2017.15.3.311. Epub 2017 Jun 12.
177. Lee HJ, Kim JH, Kim SW, Joo HA, Lee HW, Kim YS, Park SJ, Hong SP, Kim TI, Kim WH, Kim YH, **Cheon JH.**, Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet's Disease, *Dig Dis Sci.* 2017 Aug;62(8):1953-1962. doi: 10.1007/s10620-017-4606-y. Epub 2017 May 18.
178. Lee YJ, **Cheon JH.**, Kim JH, Yoo S, Lee HJ, Park SJ, Hong SP, Kim TI, Kim WH., Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis, *Yonsei Med J.* 2017 Jan;58(1):144-149. doi: 10.3349/ymj.2017.58.1.144. **(corresponding author)**
179. Park J, **Cheon JH.**, Park Y, Park SJ, Kim TI, Kim WH., Risk Factors and Outcomes of Emergency Room Visits in Intestinal Behçet's Disease, *Digestion.* 2017 Nov;96(4):231-238. doi: 10.1159/000484084. Epub 2017 Nov 2.
180. Park J, **Cheon JH.**, Park YE, Lee YJ, Lee HJ, Park SJ, Hong SP, Kim TI, Kim WH., Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behçet's disease, *Int J Colorectal Dis.* 2017 May;32(5):745-751. doi: 10.1007/s00384-016-2728-x. Epub 2016 Dec 6.
181. Park J, **Cheon JH.**, Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?, *Intest Res.* 2017 Jul;15(3):263-265. doi: 10.5217/ir.2017.15.3.263. Epub 2017 Jun 12. **(corresponding author)**
182. Park J, Kim JH, Lee HJ, Park SJ, Hong SP, **Cheon JH.**, Kim WH, Park JS, Jeon JY, Kim TI., The Effects of Physical Activity and Body Fat Mass on Colorectal Polyp Recurrence in Patients with Previous Colorectal Cancer, *Cancer Prev Res (Phila).* 2017 Aug;10(8):478-484. doi: 10.1158/1940-6207.CAPR-17-0065. Epub 2017 Jun 5. **(corresponding author)**
183. Park JW, Lee JH, Park YH, Park SJ, **Cheon JH.**, Kim WH, Kim TI., Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients, *World J Gastroenterol.* 2017 Jul 28;23(28):5196-5205. doi: 10.3748/wjg.v23.i28.5196. **(corresponding author)**
184. Park Y, **Cheon JH.**, Park YL, Ye BD, Kim YS, Han DS, Kim JS, Hong SN, Kim YH, Jeon SR, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases (KASID)., Development of a Novel Predictive Model for the Clinical Course of Crohn's Disease: Results from the CONNECT Study, *Inflamm Bowel Dis.* 2017 Jul;23(7):1071-1079. doi: 10.1097/MIB.0000000000001106. **(corresponding author)**
185. Park YE, **Cheon JH.**, Park J, Lee JH, Lee HJ, Park SJ, Kim TI, Kim WH., The outcomes and risk factors of early reoperation after initial intestinal resective surgery in patients with intestinal Behçet's disease, *Int J Colorectal Dis.* 2017 Apr;32(4):591-594. doi: 10.1007/s00384-016-2743-y. Epub 2016 Dec 27.
186. Park YE, Park SJ, Park Y, **Cheon JH.**, Kim TI, Kim WH., Impact and outcomes of nutritional support team intervention in patients with gastrointestinal disease in the intensive care unit, *Medicine (Baltimore).* 2017 Dec;96(49):e8776. doi: 10.1097/MD.00000000000008776.
187. Seo DH, Che X, Kwak MS, Kim S, Kim JH, Ma HW, Kim DH, Kim TI, Kim WH, Kim SW, **Cheon JH.**, Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease, *Sci Rep.* 2017 Apr

- 12;7(1):851. doi: 10.1038/s41598-017-00840-2. **(corresponding author)**
188. Song HJ, Moon JS, Jeon SR, Kim JO, Kim J, Cheung DY, Choi MG, Lim YJ, Shim KN, Ye BD, **Cheon JH**, Park CH, Kim HS, Kim JH, Chang DK, Do JH, Kim KO, Jang BI, Shin SJ; Korean Gut Image Study Group., Diagnostic Yield and Clinical Impact of Video Capsule Endoscopy in Patients with Chronic Diarrhea: A Korean Multicenter CAPENTRY Study, *Gut Liver*. 2017 Mar 15;11(2):253-260. doi: 10.5009/gnl16231.
189. Chung SH, Lee HW, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Usefulness of Measuring Serum Procalcitonin Levels in Patients with Inflammatory Bowel Disease, *Gut Liver*. 2016 Jul 15;10(4):574-80. doi: 10.5009/gnl15209. **(corresponding author)**
190. Jang HW, Kim HS, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease, *Intest Res*. 2016 Oct;14(4):305-313. doi: 10.5217/ir.2016.14.4.305. Epub 2016 Oct 17. **(corresponding author)**
191. Jung ES, **Cheon JH**, Lee JH, Park SJ, Jang HW, Chung SH, Park MH, Kim TG, Oh HB, Yang SK, Park SH, Han JY, Hong SP, Kim TI, Kim WH, Lee MG., HLA-C*01 is a Risk Factor for Crohn's Disease, *Inflamm Bowel Dis*. 2016 Apr;22(4):796-806. doi: 10.1097/MIB.0000000000000693.
192. Kim B, **Cheon JH**, Moon HJ, Park YR, Ye BD, Yang SK, Seo GS, Jang BI, Kim YS, Kim JS, Han DS, Kim YH, Kim WH., Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study, *J Gastroenterol Hepatol*. 2016 Jan;31(1):126-32. doi: 10.1111/jgh.13169.
193. Kim B, Choi AR, Park SJ, **Cheon JH**, Kim TI, Kim WH, Hong SP., Long-Term Outcome and Surveillance Colonoscopy after Successful Endoscopic Treatment of Large Sessile Colorectal Polyps, *Yonsei Med J*. 2016 Sep;57(5):1106-14. doi: 10.3349/ymj.2016.57.5.1106.
194. Kim B, Kim EH, Park SJ, **Cheon JH**, Kim TI, Kim WH, Kim H, Hong SP., The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients, *Medicine (Baltimore)*. 2016 Sep;95(37):e4373. doi: 10.1097/MD.00000000000004373.
195. Kim DH, **Cheon JH.**, Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?, *Yonsei Med J*. 2016 Jan;57(1):22-32. doi: 10.3349/ymj.2016.57.1.22. **(corresponding author)**
196. Kim DH, Kim B, Choi JH, Park SJ, Hong SP, **Cheon JH**, Kim WH, Kim TI., Tumor characteristics associated with malignant large bowel obstruction in stage IV colorectal cancer patients undergoing chemotherapy, *Int J Colorectal Dis*. 2016 Nov;31(11):1767-1774. doi: 10.1007/s00384-016-2638-y. Epub 2016 Sep 9. **(corresponding author)**
197. Kim DH, Park SJ, **Cheon JH**, Kim TI, Kim WH, Hong SP., Does a Pre-Training Program Influence Colonoscopy Proficiency during Fellowship?, *PLoS One*. 2016 Oct 20;11(10):e0164360. doi: 10.1371/journal.pone.0164360. eCollection 2016. **(corresponding author)**
198. Kim JH, **Cheon JH**, Park Y, Lee HJ, Park SJ, Kim TI, Kim WH., Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission, *Scand J Gastroenterol*. 2016 Sep;51(9):1069-74. doi: 10.3109/00365521.2016.1150503. Epub 2016 Feb 19. **(corresponding author)**
199. Kim JH, **Cheon JH.**, Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis, *Gut Liver*. 2016 Mar;10(2):162-3. doi: 10.5009/gnl16024. **(corresponding author)**
200. Kim YI, Lee BR, **Cheon JH**, Kwon BE, Kweon MN, Ko HJ, Chang SY., Compensatory roles of CD8+ T cells and plasmacytoid dendritic cells in gut immune regulation for reduced function of CD4+ Tregs, *Oncotarget*. 2016 Mar 8;7(10):10947-61. doi: 10.18632/oncotarget.7510. **(1st author)**
201. Kwon JH, Im JP, Ye BD, **Cheon JH**, Jang HJ, Lee KM, Kim YS, Kim SW, Kim YH, Song GA, Han DS, Kim WH, Kim JS., Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study, *Gut Liver*. 2016 Jul 15;10(4):595-603. doi: 10.5009/gnl15411. **(corresponding author)**
202. Lee HJ, Oh SH, Jang HW, Kwon JH, Lee KJ, Kim CH, Park SJ, Hong SP, **Cheon JH**, Kim TI, Kim WH., Long-Term Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Dextran Sulfate Sodium-Induced Murine Chronic Colitis, *Gut Liver*. 2016 May 23;10(3):412-9. doi: 10.5009/gnl15229.
203. Lee HW, Chung SH, Moon CM, Che X, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease, *Medicine (Baltimore)*. 2016 Jun;95(23):e3772. doi: 10.1097/MD.00000000000003772. **(corresponding author)**
204. Park HJ, Jung ES, Kong KA, Park EM, **Cheon JH**, Choi JH., Identification of OCTN2 variants and their association with phenotypes of Crohn's disease in a Korean population, *Sci Rep*. 2016 Mar 11;6:22887. doi: 10.1038/srep22887. **(corresponding author)**
205. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group., Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis, *N Engl J Med*. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248.
206. Sohn IW, Kim ST, Kim B, Lee HJ, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Efficacy of Adalimumab in Korean Patients with Crohn's Disease, *Gut Liver*. 2016 Mar;10(2):255-61. doi: 10.5009/gnl15165.

207. Yang JY, Kim MS, Kim E, **Cheon JH**, Lee YS, Kim Y, Lee SH, Seo SU, Shin SH, Choi SS, Kim B, Chang SY, Ko HJ, Bae JW, Kweon MN., Enteric Viruses Ameliorate Gut Inflammation via Toll-like Receptor 3 and Toll-like Receptor 7-Mediated Interferon- β Production, *Immunity*. 2016 Apr 19;44(4):889-900. doi: 10.1016/j.immuni.2016.03.009. Epub 2016 Apr 12.
208. Byun JM, Lee CK, Rhee SY, Kim HJ, Im JP, Park DI, Eun CS, Jung SA, Shin JE, Lee KM, **Cheon JH**., Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor- α inhibitor, *Scand J Gastroenterol*. 2015 Mar;50(3):312-20. doi: 10.3109/00365521.2014.1000960. Epub 2015 Jan 12.
209. Chang S, **Cheon JH**., A clinical significance of assessing cytomegalovirus infection status in patients with ulcerative colitis, *Intest Res*. 2015 Jan;13(1):2-3. doi: 10.5217/ir.2015.13.1.2. Epub 2015 Jan 29. **(corresponding author)**
210. **Cheon JH**, Kim WH., An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease, *Curr Opin Rheumatol*. 2015 Jan;27(1):24-31. doi: 10.1097/BOR.000000000000125.
211. **Cheon JH**., Advances in the Endoscopic Assessment of Inflammatory Bowel Diseases: Cooperation between Endoscopic and Pathologic Evaluations, *J Pathol Transl Med*. 2015 May;49(3):209-17. doi: 10.4132/jptm.2015.04.09. Epub 2015 May 15.
212. Chung SH, Park SU, **Cheon JH**, Kim ER, Byeon JS, Ye BD, Keum B, Shim KN, Jung SA, Kim JO, Jeon SR, Song HJ, Moon JS, Chang DK., Clinical Characteristics and Treatment Outcomes of Cryptogenic Multifocal Ulcerous Stenosing Enteritis in Korea, *Dig Dis Sci*. 2015 Sep;60(9):2740-5. doi: 10.1007/s10620-015-3595-y. Epub 2015 Feb 24. **(corresponding author)**
213. Doh YS, Kim YS, Bae SI, Im JP, **Cheon JH**, Ye BD, Kim JW, Park YS, Lee JH, Kim YH, Kim JS, Han DS, Kim WH., The clinical characteristics of patients with free perforation in Korean Crohn's disease: results from the CONNECT study, *BMC Gastroenterol*. 2015 Mar 18;15:31. doi: 10.1186/s12876-015-0262-x. **(corresponding author)**
214. Jang HW, Park SJ, Hong SP, **Cheon JH**, Kim WH, Kim TI., Risk Factors for Recurrent High-Risk Polyps after the Removal of High-Risk Polyps at Initial Colonoscopy, *Yonsei Med J*. 2015 Nov;56(6):1559-65. doi: 10.3349/ymj.2015.56.6.1559.
215. Jung YS, Park DI, Hong SN, Kim ER, Kim YH, **Cheon JH**, Eun CS, Han DS, Lee CK, Kim JH, Huh KC, Yoon SM, Song HJ, Shin JE, Jeon SR., Predictors of Urgent Findings on Abdominopelvic CT in Patients with Crohn's Disease Presenting to the Emergency Department, *Dig Dis Sci*. 2015 Apr;60(4):929-35. doi: 10.1007/s10620-014-3298-9. Epub 2014 Jul 27.
216. Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, **Cheon JH**, Kang HW, Kim JW., Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study, *J Gastroenterol Hepatol*. 2015 Dec;30(12):1705-12. doi: 10.1111/jgh.12997.
217. Jung YS, Park DI, Ye BD, **Cheon JH**, Kim YS, Kim YH, Kim JS, Chae HS, Baik GH, Han DS., Long-term clinical outcomes of urban versus rural environment in Korean patients with Crohn's disease: results from the CONNECT study, *J Crohns Colitis*. 2015 Mar;9(3):246-51. doi: 10.1093/ecco-jcc/jjv003. Epub 2015 Jan 17.
218. Kim B, Park SJ, Hong SP, **Cheon JH**, Kim TI, Kim WH., Overlooked Management and Risk Factors for Anemia in Patients with Intestinal Behçet's Disease in Actual Clinical Practice, *Gut Liver*. 2015 Nov 23;9(6):750-5. doi: 10.5009/gnl14193.
219. Kim B, Park SJ, Hong SP, **Cheon JH**, Kim WH, Kim TI., The effect of prediagnostic aspirin use on the prognosis of stage III colorectal cancer, *Int J Clin Exp Med*. 2015 Aug 15;8(8):13435-45. eCollection 2015.
220. Kim EH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH**., Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study, *Gut Liver*. 2015 Sep 23;9(5):601-6. doi: 10.5009/gnl14120. **(corresponding author)**
221. Lee HJ, Park SJ, **Cheon JH**, Kim TI, Kim WH, Hong SP., What is the necessity of endoscopist for successful endoscopic stenting in patients with malignant colorectal obstruction?, *Int J Colorectal Dis*. 2015 Jan;30(1):119-25. doi: 10.1007/s00384-014-2060-2. Epub 2014 Nov 8.
222. Lee HW, **Cheon JH**, Lee HJ, Park SJ, Hong SP, Kim TI, Kim WH., Postoperative Effects of Thiopurines in Patients with Intestinal Behçet's Disease, *Dig Dis Sci*. 2015 Dec;60(12):3721-7. doi: 10.1007/s10620-015-3799-1. Epub 2015 Jul 22.
223. Lee JH, **Cheon JH**, Hong SP, Kim TI, Kim WH., Seasonal Variation in Flares of Intestinal Behçet's Disease, *Dig Dis Sci*. 2015 Nov;60(11):3373-8. doi: 10.1007/s10620-015-3863-x. Epub 2015 Sep 19. **(corresponding author)**
224. Lee JW, Im JP, **Cheon JH**, Kim YS, Kim JS, Han DS., Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future, *Intest Res*. 2015 Jul;13(3):213-8. doi: 10.5217/ir.2015.13.3.213. Epub 2015 Jun 9. **(corresponding author)**
225. Lee S, Lee TA, Lee E, Kang S, Park A, Kim SW, Park HJ, Yoon JH, Ha SJ, Park T, Lee JS, **Cheon JH**, Park B., Identification of a subnuclear body involved in sequence-specific cytokine RNA processing, *Nat Commun*. 2015 Jan 5;6:5791. doi: 10.1038/ncomms6791. **(corresponding author)**
226. Lim YJ, Lee OY, Jeon YT, Lim CY, Cheung DY, **Cheon JH**, Ye BD, Song HJ, Kim JS, Do JH, Lee KJ, Shim KN, Chang DK, Park CH, Jang BI, Moon JS, Chun HJ, Choi MG, Kim JO; Korean Gut Image Study Group., Indications for

- Detection, Completion, and Retention Rates of Small Bowel Capsule Endoscopy Based on the 10-Year Data from the Korean Capsule Endoscopy Registry, *Clin Endosc.* 2015 Sep;48(5):399-404. doi: 10.5946/ce.2015.48.5.399. Epub 2015 Sep 30. **(corresponding author)**
227. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, **Cheon JH**, Cho J, Dayani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JY, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK; International Multiple Sclerosis Genetics Consortium; International IBD Genetics Consortium; Barrett JC, Alizadeh BZ, Parkes M, Bk T, Daly MJ, Kubo M, Anderson CA, Weersma RK., Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations, *Nat Genet.* 2015 Sep;47(9):979-986. doi: 10.1038/ng.3359. Epub 2015 Jul 20.
228. Moon CM, Jung SA, Kim SE, Song HJ, Jung Y, Ye BD, **Cheon JH**, Kim YS, Kim YH, Kim JS, Han DS; CONNECT study group., Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn's Disease Patients: Results from the CONNECT Study, *PLoS One.* 2015 Dec 8;10(12):e0144390. doi: 10.1371/journal.pone.0144390. eCollection 2015.
229. Park CH, Yoon JY, Park SJ, **Cheon JH**, Kim TI, Lee SK, Lee YC, Kim WH, Hong SP., Clinical efficacy of endoscopic treatment for benign colorectal stricture: balloon dilatation versus stenting, *Gut Liver.* 2015 Jan;9(1):73-9. doi: 10.5009/gnl13326.
230. Park MS, Kim DH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH**., Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance, *Dig Dis Sci.* 2015 Jan;60(1):195-204. doi: 10.1007/s10620-014-3355-4. Epub 2014 Sep 20.
231. Park S, Noh YH, Rha SY, Kim WH, **Cheon JH**., Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study, *Intest Res.* 2015 Jul;13(3):274-81. doi: 10.5217/ir.2015.13.3.274. Epub 2015 Jun 9. **(corresponding author)**
232. Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, **Cheon JH**, Im JP, Kim YS, Lee SY, Lee SJ., Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea, *Expert Rev Gastroenterol Hepatol.* 2015;9 Suppl 1:35-44. doi: 10.1586/17474124.2015.1091309.
233. Park Y, Jeon TJ, Park JY, Park SJ, **Cheon JH**, Kim TI, Kim WH, Hong SP., Comparison of clipping with and without epinephrine injection for the prevention of post-polypectomy bleeding in pedunculated colon polyps, *J Gastroenterol Hepatol.* 2015 Oct;30(10):1499-506. doi: 10.1111/jgh.12994. **(corresponding author)**
234. Shim KN, Song EM, Jeon YT, Kim JO, Jeon SR, Chang DK, Song HJ, Lim YJ, Kim JS, Ye BD, Park CH, Jeon SW, **Cheon JH**, Lee KJ, Kim JH, Jang BI, Moon JS, Chun HJ, Choi MG; Korean Gut Image Study Group., Long-Term Outcomes of NSAID-Induced Small Intestinal Injury Assessed by Capsule Endoscopy in Korea: A Nationwide Multicenter Retrospective Study, *Gut Liver.* 2015 Nov 23;9(6):727-33. doi: 10.5009/gnl14134. **(corresponding author)**
235. Yang SK, Hong M, Choi H, Zhao W, Jung Y, Haritunians T, Ye BD, Kim KJ, Park SH, Lee I, Kim WH, **Cheon JH**, Kim YH, Jang BI, Kim HS, Choi JH, Koo JS, Lee JH, Jung SA, Shin HD, Kang D, Youn HS, Taylor KD, Rotter JI, Liu J, McGovern DP, Song K., Immunochip analysis identification of 6 additional susceptibility loci for Crohn's disease in Koreans, *Inflamm Bowel Dis.* 2015 Jan;21(1):1-7. doi: 10.1097/MIB.0000000000000268.
236. **Cheon JH**, Kim YS, Ye BD, Lee KM, Kim YH, Kim JS, Han DS, Kim WH., Crohn's Disease Clinical Network and Cohort (CONNECT) Study: The First Step Toward Nationwide Multicenter Research of Crohn's Disease in Korea, *Intest Res.* 2014 Jul;12(3):173-5. doi: 10.5217/ir.2014.12.3.173. **(corresponding author)**
237. Chung SH, Park SJ, Lee HS, Hong SP, **Cheon JH**, Kim TI, Kim WH., Similar clinical characteristics of familial and sporadic inflammatory bowel disease in South Korea, *World J Gastroenterol.* 2014 Dec 7;20(45):17120-6. doi: 10.3748/wjg.v20.i45.17120.
238. Jang HW, Park SJ, **Cheon JH**, Kim TI, Kim WH, Hong SP., Does magnifying narrow-band imaging or magnifying chromoendoscopy help experienced endoscopists assess invasion depth of large sessile and flat polyps?, *Dig Dis Sci.* 2014 Jul;59(7):1520-8. doi: 10.1007/s10620-014-3090-x. Epub 2014 May 20.
239. Jung YS, Park DI, Moon CM, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH**., Radiation exposure from abdominal imaging studies in patients with intestinal Behçet disease, *Gut Liver.* 2014 Jul;8(4):380-7. doi: 10.5009/gnl.2014.8.4.380. Epub 2013 Dec 24.
240. Kim B, Park SJ, **Cheon JH**, Kim TI, Kim WH, Hong SP., Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer, *World J Gastroenterol.* 2014 Apr 21;20(15):4370-6. doi: 10.3748/wjg.v20.i15.4370.
241. Kim B, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH**., Proximal disease extension and related predicting factors in ulcerative proctitis, *Scand J Gastroenterol.* 2014 Feb;49(2):177-83. doi: 10.3109/00365521.2013.867360. Epub 2013 Dec 11. **(corresponding author)**
242. Kim DH, Lee JH, Cha YJ, Park SJ, **Cheon JH**, Kim TI, Kim H, Kim WH, Hong SP., Surveillance strategy for rectal neuroendocrine tumors according to recurrence risk stratification, *Dig Dis Sci.* 2014 Apr;59(4):850-6. doi: 10.1007/s10620-013-2972-7. Epub 2013 Dec 10.
243. Kim DH, Park SJ, Park JJ, Yun YH, Hong SP, Kim TI, Kim WH, **Cheon JH**., Effect of follow-up endoscopy on the

- outcomes of patients with inflammatory bowel disease, *Dig Dis Sci.* 2014 Oct;59(10):2514-22. doi: 10.1007/s10620-014-3197-0. Epub 2014 May 18. **(corresponding author)**
244. Kim HH, Kim YS, Han DS, Kim YH, Kim WH, Kim JS, Kim H, Kim HS, Park YS, Song HJ, Shin SJ, Yang SK, Ye BD, Eun CS, Lee KM, Lee SH, Jang BI, Jung SA, **Cheon JH**, Choi CH, Huh K; IBD Study Group of the Korean Association for the Study of Intestinal Diseases., Clinical differences in *Clostridium difficile* infection based on age: a multicenter study, *Scand J Infect Dis.* 2014 Jan;46(1):46-51. doi: 10.3109/00365548.2013.840918. Epub 2013 Oct 10. **(corresponding author)**
245. Kim SB, Park SJ, Chung SH, Hahn KY, Moon DC, Hong SP, **Cheon JH**, Kim TI, Kim WH., Vaccination and complementary and alternative medicine in patients with inflammatory bowel disease, *Intest Res.* 2014 Apr;12(2):124-30. doi: 10.5217/ir.2014.12.2.124. Epub 2014 Apr 29. **(corresponding author)**
246. Kim YS, Kim YH, Kim JS, Jeong SY, Park SJ, **Cheon JH**, Ye BD, Jung SA, Park YS, Choi CH, Kim KO, Jang BI, Han DS, Yang SK, Kim WH., Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study, *Gut Liver.* 2014 Nov;8(6):643-7. doi: 10.5009/gnl13427. Epub 2014 Nov 15.
247. Kwak MS, Kim DH, Park SJ, Kim TI, Hong SP, Kim WH, **Cheon JH**., Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease, *BMC Gastroenterol.* 2014 May 3;14:85. doi: 10.1186/1471-230X-14-85.
248. Lee BR, Chang SY, Hong EH, Kwon BE, Kim HM, Kim YJ, Lee J, Cho HJ, **Cheon JH**, Ko HJ., Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells, *Oncotarget.* 2014 Dec 15;5(23):12331-45. doi: 10.18632/oncotarget.2589. **(corresponding author)**
249. Lee HJ, Park SJ, Min BS, **Cheon JH**, Kim TI, Kim NK, Kim WH, Hong SP., The role of primary colectomy after successful endoscopic stenting in patients with obstructive metastatic colorectal cancer, *Dis Colon Rectum.* 2014 Jun;57(6):694-9. doi: 10.1097/DCR.000000000000061. **(corresponding author)**
250. Lee HJ, Shin HS, Jang HW, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH**., Correlation between soluble triggering receptor expressed on myeloid cells-1 and endoscopic activity in intestinal Behçet's disease, *Yonsei Med J.* 2014 Jul;55(4):960-6. doi: 10.3349/ymj.2014.55.4.960.
251. Lee S, Park SJ, **Cheon JH**, Kim TI, Kim WH, Kang DR, Hong SP., Child-Pugh score is an independent risk factor for immediate bleeding after colonoscopic polypectomy in liver cirrhosis, *Yonsei Med J.* 2014 Sep;55(5):1281-8. doi: 10.3349/ymj.2014.55.5.1281.
252. Moon CM, Kwon JH, Kim JS, Oh SH, Jin Lee K, Park JJ, Pil Hong S, **Cheon JH**, Kim TI, Kim WH., Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPAR γ in colorectal cancer, *Int J Cancer.* 2014 Feb 1;134(3):519-29. doi: 10.1002/ijc.28381. Epub 2013 Aug 7.
253. Park JJ, Kwon JH, Oh SH, Choi J, Moon CM, Ahn JB, Hong SP, **Cheon JH**, Kim TI, Kim H, Kim WH., Differential expression of CD133 based on microsatellite instability status in human colorectal cancer, *Mol Carcinog.* 2014 Feb;53 Suppl 1:E1-10. doi: 10.1002/mc.21971. Epub 2012 Oct 12.
254. Park SJ, Kim WH, **Cheon JH**., Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives, *World J Gastroenterol.* 2014 Sep 7;20(33):11525-37. doi: 10.3748/wjg.v20.i33.11525. **(corresponding author)**
255. Park W, Kim B, Park SJ, **Cheon JH**, Kim TI, Kim WH, Hong SP., Conventional endoscopic features are not sufficient to differentiate small, early colorectal cancer, *World J Gastroenterol.* 2014 Jun 7;20(21):6586-93. doi: 10.3748/wjg.v20.i21.6586.
256. Seo GS, Jiang WY, Park PH, Sohn DH, **Cheon JH**, Lee SH., Hirsutenone reduces deterioration of tight junction proteins through EGFR/Akt and ERK1/2 pathway both converging to HO-1 induction, *Biochem Pharmacol.* 2014 Jul 15;90(2):115-25. doi: 10.1016/j.bcp.2014.05.006. Epub 2014 May 20. **(corresponding author)**
257. van Halsema EE, van Hooff JE, Small AJ, Baron TH, García-Cano J, **Cheon JH**, Lee MS, Kwon SH, Mucci-Hennekinne S, Fockens P, Dijkgraaf MG, Repici A., Perforation in colorectal stenting: a meta-analysis and a search for risk factors, *Gastrointest Endosc.* 2014 Jun;79(6):970-82.e7; quiz 983.e2, 983.e5. doi: 10.1016/j.gie.2013.11.038. Epub 2014 Mar 18. **(corresponding author)**
258. Yang SK, Hong M, Zhao W, Jung Y, Baek J, Tayebi N, Kim KM, Ye BD, Kim KJ, Park SH, Lee I, Lee EJ, Kim WH, **Cheon JH**, Kim YH, Jang BI, Kim HS, Choi JH, Koo JS, Lee JH, Jung SA, Lee YJ, Jang JY, Shin HD, Kang D, Youn HS, Liu J, Song K., Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations, *Gut.* 2014 Jan;63(1):80-7. doi: 10.1136/gutjnl-2013-305193. Epub 2013 Jul 14. **(corresponding author)**
259. Yim SM, Kim DH, Lee HJ, Jang HW, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH**., Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease, *Dig Dis Sci.* 2014 Oct;59(10):2529-35. doi: 10.1007/s10620-014-3198-z. Epub 2014 May 18. **(corresponding author)**
260. Yoon JY, Park SJ, **Cheon JH**., Effect of Colostrum on the Symptoms and Mucosal Permeability in Patients with Irritable Bowel Syndrome: A Randomized Placebo-controlled Study, *Intest Res.* 2014 Jan;12(1):80-2. doi: 10.5217/ir.2014.12.1.80. Epub 2014 Jan 28. **(corresponding author)**

261. Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis, *Dig Dis Sci.* 2014 Apr;59(4):829-37. doi: 10.1007/s10620-013-2907-3. Epub 2013 Dec 19. **(corresponding author)**
262. Bok HJ, Lee JH, Shin JK, Jeon SM, Park JJ, Moon CM, Hong SP, **Cheon JH.** Kim TI, Kim WH., [Clinicopathologic features of colorectal cancer combined with synchronous and metachronous gastric cancer], *Korean J Gastroenterol.* 2013 Jul;62(1):27-32. doi: 10.4166/kjg.2013.62.1.27.
263. **Cheon JH.** Hahm KB., Perfecting video capsule endoscopy: is there need for training?, *Clin Endosc.* 2013 Nov;46(6):599-600. doi: 10.5946/ce.2013.46.6.599. Epub 2013 Nov 19. **(1st author)**
264. **Cheon JH.**, Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives, *J Gastroenterol Hepatol.* 2013 Feb;28(2):220-6. doi: 10.1111/jgh.12053. **(1st author)**
265. Choi AR, Yoon JY, Lee HJ, Jang HW, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Clinical outcomes following secondary self-expandable metal stent (SEMS) insertion due to previous stent migration in malignant colorectal obstruction, *Surg Endosc.* 2013 Sep;27(9):3288-96. doi: 10.1007/s00464-013-2907-6. Epub 2013 Mar 22. **(corresponding author)**
266. Chung SH, Park SJ, **Cheon JH.** Park MS, Hong SP, Kim TI, Kim WH., Factors predictive of high-risk adenomas at the third colonoscopy after initial adenoma removal, *J Korean Med Sci.* 2013 Sep;28(9):1345-50. doi: 10.3346/jkms.2013.28.9.1345. Epub 2013 Aug 28.
267. Chung SH, Park SJ, Hong JS, Hwang JY, Lee SA, Kim KR, Lee HS, Hong SP, **Cheon JH.** Kim TI, Kim WH., Comparison of double pants with single pants on satisfaction with colonoscopy, *World J Gastroenterol.* 2013 Jul 14;19(26):4177-84. doi: 10.3748/wjg.v19.i26.4177.
268. Chung SH, Park SJ, Hong SP, **Cheon JH.** Kim TI, Kim WH., Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis, *World J Gastroenterol.* 2013 Aug 28;19(32):5389-92. doi: 10.3748/wjg.v19.i32.5389.
269. Jeon HH, Lee HJ, Jang HW, Yoon JY, Jung YS, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis, *World J Gastroenterol.* 2013 Jan 14;19(2):265-73. doi: 10.3748/wjg.v19.i2.265. **(corresponding author)**
270. Jung YS, **Cheon JH.** Park SJ, Hong SP, Kim TI, Kim WH., Clinical course of intestinal Behçet's disease during the first five years, *Dig Dis Sci.* 2013 Feb;58(2):496-503. doi: 10.1007/s10620-012-2351-9. Epub 2012 Aug 17.
271. Jung YS, **Cheon JH.** Park SJ, Hong SP, Kim TI, Kim WH., Long-term clinical outcomes of Crohn's disease and intestinal Behçet's disease, *Inflamm Bowel Dis.* 2013 Jan;19(1):99-105. doi: 10.1002/ibd.22991. **(corresponding author)**
272. Kang HP, Lee H, Oh TG, Lee KJ, Park SJ, Chung MJ, Kim SU, Lee H, Park JC, Hong SP, Park JY, Park JY, Bang S, Kim DY, **Cheon JH.** Ahn SH, Kim TI, Park SW, Song SY., The use of health functional foods in gastrointestinal cancer patients, *Clin Nutr Res.* 2013 Jan;2(1):19-25. doi: 10.7762/cnr.2013.2.1.19. Epub 2013 Jan 29. **(corresponding author)**
273. Kim DH, **Cheon JH.** Park JJ, Yoon JY, Moon CM, Hong SP, Kim TI, Kim WH., Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn's disease, *Gut Liver.* 2013 Jan;7(1):58-65. doi: 10.5009/gnl.2013.7.1.58. Epub 2013 Jan 11.
274. Kim SW, Park KC, Jeon SM, Ohn TB, Kim TI, Kim WH, **Cheon JH.**, Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer, *Cell Oncol (Dordr).* 2013 Apr;36(2):169-78. doi: 10.1007/s13402-013-0124-x. Epub 2013 Feb 2. **(corresponding author)**
275. Korean Gut Image Study Group; Lim YJ, Joo YS, Jung DY, Ye BD, Kim JH, **Cheon JH.** Kim SE, Do JH, Jang BI, Moon JS, Kim JO, Chun HJ, Choi MG., Learning curve of capsule endoscopy, *Clin Endosc.* 2013 Nov;46(6):633-6. doi: 10.5946/ce.2013.46.6.633. Epub 2013 Nov 19.
276. Lee JH, **Cheon JH.** Jeon SW, Ye BD, Yang SK, Kim YH, Lee KM, Im JP, Kim JS, Lee CK, Kim HJ, Kim EY, Kim KO, Jang BI, Kim WH., Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study, *Inflamm Bowel Dis.* 2013 Aug;19(9):1833-8. doi: 10.1097/MIB.0b013e31828f19c9. **(corresponding author)**
277. Lim SM, Nam CM, Kim YN, Lee SA, Kim EH, Hong SP, Kim TI, Kim WH, **Cheon JH.**, The effect of the menstrual cycle on inflammatory bowel disease: a prospective study, *Gut Liver.* 2013 Jan;7(1):51-7. doi: 10.5009/gnl.2013.7.1.51. Epub 2013 Jan 11. **(corresponding author)**
278. Moon CM, Shin DJ, Kim SW, Son NH, Park A, Park B, Jung ES, Kim ES, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population, *Inflamm Bowel Dis.* 2013 Jan;19(1):106-14. doi: 10.1002/ibd.22972. **(corresponding author)**
279. Moon CM, Shin DJ, Son NH, Shin ES, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Genetic variants in the IL12B gene are associated with inflammatory bowel diseases in the Korean population, *J Gastroenterol Hepatol.* 2013 Oct;28(10):1588-94. doi: 10.1111/jgh.12214. **(corresponding author)**
280. Park JJ, Kim WH, **Cheon JH.**, Outcome predictors for intestinal Behçet's disease, *Yonsei Med J.* 2013 Sep;54(5):1084-90. doi: 10.3349/ymj.2013.54.5.1084. **(corresponding author)**
281. Park MS, Kim WJ, Huh JH, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Crohn's duodeno-colonic fistula preoperatively closed using a detachable endoloop and hemoclips: a case report, *Korean J Gastroenterol.* 2013

- Feb;61(2):97-102. doi: 10.4166/kjg.2013.61.2.97. **(corresponding author)**
282. Park YH, Chung WS, Lim JS, Park SJ, **Cheon JH**, Kim TI, Kim WH, Hong SP., Diagnostic role of computed tomographic enterography differentiating crohn disease from intestinal tuberculosis, *J Comput Assist Tomogr*. 2013 Sep-Oct;37(5):834-9. doi: 10.1097/RCT.0b013e31829e0292. **(corresponding author)**
283. Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH**., Outcomes of secondary self-expandable metal stents versus surgery after delayed initial palliative stent failure in malignant colorectal obstruction, *Digestion*. 2013;88(1):46-55. doi: 10.1159/000351208. Epub 2013 Jul 19. **(corresponding author)**
284. Heo HM, Park CH, Lim JS, Lee JH, Kim BK, **Cheon JH**, Kim TI, Kim WH, Hong SP., The role of capsule endoscopy after negative CT enterography in patients with obscure gastrointestinal bleeding, *Eur Radiol*. 2012 Jun;22(6):1159-66. doi: 10.1007/s00330-011-2374-1. Epub 2012 Jan 22.
285. Hong SP, **Cheon JH**, Kim TI, Song SY, Kim WH., Comparison of the diagnostic yield of "MiroCam" and "PillCam SB" capsule endoscopy, *Hepatogastroenterology*. 2012 May;59(115):778-81. doi: 10.5754/hge10472.
286. Hong SP, Min BS, Kim TI, **Cheon JH**, Kim NK, Kim H, Kim WH., The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer, *Eur J Cancer*. 2012 May;48(8):1235-43. doi: 10.1016/j.ejca.2011.10.005. Epub 2011 Nov 7. **(corresponding author)**
287. Jang HW, Kim YN, Nam CM, Lee HJ, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH**., Factors affecting colonoscope insertion time in patients with or without a colostomy after left-sided colorectal resection, *Dig Dis Sci*. 2012 Dec;57(12):3219-25. doi: 10.1007/s10620-012-2257-6. Epub 2012 Jun 8. **(corresponding author)**
288. Jeon SM, **Cheon JH**., Rectal carcinoid tumors: pitfalls of conventional polypectomy, *Clin Endosc*. 2012 Mar;45(1):2-3. doi: 10.5946/ce.2012.45.1.2. Epub 2012 Mar 31. **(corresponding author)**
289. Jung YS, **Cheon JH**, Hong SP, Kim TI, Kim WH., Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease, *Inflamm Bowel Dis*. 2012 Apr;18(4):750-7. doi: 10.1002/ibd.21757. Epub 2011 May 25. **(corresponding author)**
290. Jung YS, Hong SP, Kim TI, Kim WH, **Cheon JH**., Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease, *J Clin Gastroenterol*. 2012 May-Jun;46(5):e38-45. doi: 10.1097/MCG.0b013e3182431d56. **(corresponding author)**
291. Jung YS, Hong SP, Kim TI, Kim WH, **Cheon JH**., Early versus late surgery in patients with intestinal Behçet disease, *Dis Colon Rectum*. 2012 Jan;55(1):65-71. doi: 10.1097/DCR.0b013e318238b57e. **(corresponding author)**
292. Jung YS, Park JJ, Kim SW, Hong SP, Kim TI, Kim WH, **Cheon JH**., Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases, *Dig Liver Dis*. 2012 Nov;44(11):897-903. doi: 10.1016/j.dld.2012.05.011. Epub 2012 Jun 19. **(corresponding author)**
293. Jung YS, Yoon JY, Hong SP, Kim TI, Kim WH, **Cheon JH**., Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet's disease, *Inflamm Bowel Dis*. 2012 Jun;18(6):1064-71. doi: 10.1002/ibd.21833. Epub 2011 Jul 26. **(corresponding author)**
294. Kim BK, Hong SP, Heo HM, Kim JY, Hur H, Lee KY, **Cheon JH**, Kim TI, Kim WH., Endoscopic stenting is not as effective for palliation of colorectal obstruction in patients with advanced gastric cancer as emergency surgery, *Gastrointest Endosc*. 2012 Feb;75(2):294-301. doi: 10.1016/j.gie.2011.09.026. Epub 2011 Dec 9. **(corresponding author)**
295. Kim ES, Kim SW, Moon CM, Park JJ, Kim TI, Kim WH, **Cheon JH**., Interactions between IL17A, IL23R, and STAT4 polymorphisms confer susceptibility to intestinal Behcet's disease in Korean population, *Life Sci*. 2012 May 22;90(19-20):740-6. doi: 10.1016/j.lfs.2012.03.017. Epub 2012 Mar 27. **(corresponding author)**
296. Kim JH, Oh SH, Kim EJ, Park SJ, Hong SP, **Cheon JH**, Kim TI, Kim WH., The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myeloid cells in the colorectal cancer microenvironment, *Biochem Biophys Res Commun*. 2012 Jun 22;423(1):60-6. doi: 10.1016/j.bbrc.2012.05.081. Epub 2012 May 22. **(corresponding author)**
297. Kim SW, Kim ES, Moon CM, Kim TI, Kim WH, **Cheon JH**., Abnormal genetic and epigenetic changes in signal transducer and activator of transcription 4 in the pathogenesis of inflammatory bowel diseases, *Dig Dis Sci*. 2012 Oct;57(10):2600-7. doi: 10.1007/s10620-012-2199-z. Epub 2012 May 9. **(corresponding author)**
298. Kim YS, Kim YH, Kim JS, **Cheon JH**, Ye BD, Jung SA, Park YS, Choi CH, Jang BI, Han DS, Yang SK, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases(KASID), Korea., Cytomegalovirus infection in patients with new onset ulcerative colitis: a prospective study, *Hepatogastroenterology*. 2012 Jun;59(116):1098-101. doi: 10.5754/hge10217. **(corresponding author)**
299. Kim YS, Kim YH, Kim JS, **Cheon JH**, Ye BD, Jung SA, Park YS, Choi CH, Jang BI, Han DS, Yang SK, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases., The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study, *J Clin Gastroenterol*. 2012 Jan;46(1):51-6. doi: 10.1097/MCG.0b013e3182160c9c.
300. Lee DJ, Kim B, Lee JH, Park SJ, Hong SP, **Cheon JH**, Kim TI, Kim WH., [The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes], *Korean J Gastroenterol*. 2012 Dec;60(6):355-

61. doi: 10.4166/kjg.2012.60.6.355.
301. Lee HJ, Jung ES, Lee JH, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis, *Hepatogastroenterology*. 2012 Jul-Aug;59(117):1415-20. doi: 10.5754/hge10680.
302. Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, Hong SP, Kim TI, Kim WH, Nam CM, **Cheon JH.**, Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease, *World J Gastroenterol*. 2012 Oct 28;18(40):5771-8. doi: 10.3748/wjg.v18.i40.5771. **(corresponding author)**
303. Lee JH, Jeon SM, Hong SP, **Cheon JH.**, Kim TI, Kim WH., Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer, *Dig Liver Dis*. 2012 Dec;44(12):1042-7. doi: 10.1016/j.dld.2012.06.007. Epub 2012 Jul 11. **(corresponding author)**
304. Lee JH, Kim TI, Jeon SM, Hong SP, **Cheon JH.**, Kim WH., The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus, *Int J Cancer*. 2012 Aug 1;131(3):752-9. doi: 10.1002/ijc.26421. Epub 2011 Oct 20. **(corresponding author)**
305. Lee JH, Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, The learning curve for colorectal stent insertion for the treatment of malignant colorectal obstruction, *Gut Liver*. 2012 Jul;6(3):328-33. doi: 10.5009/gnl.2012.6.3.328. Epub 2012 May 22. **(corresponding author)**
306. Lee SK, Yang KM, **Cheon JH.**, Kim TI, Kim WH., [Anti-inflammatory mechanism of *Lactobacillus rhamnosus* GG in lipopolysaccharide-stimulated HT-29 cell], *Korean J Gastroenterol*. 2012 Aug;60(2):86-93. doi: 10.4166/kjg.2012.60.2.86.
307. Lee TH, Lee JS, Jo Y, Park KS, **Cheon JH.**, Kim YS, Jang JY, Kang YW., Superior mesenteric artery syndrome: where do we stand today?, *J Gastrointest Surg*. 2012 Dec;16(12):2203-11. doi: 10.1007/s11605-012-2049-5. Epub 2012 Oct 18.
308. Park H, Park JJ, Moon CM, Hong SP, Lim JS, Kim MJ, Kim TL, Kim WH, **Cheon JH.**, Diagnostic utility of computer tomographic enterography for patients presenting with unexplained gastrointestinal symptoms, *Hepatogastroenterology*. 2012 Sep;59(118):1869-73. doi: 10.5754/hge10833. **(corresponding author)**
309. Park JJ, **Cheon JH.**, Hong SP, Kim TI, Kim WH., Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease, *Dig Dis Sci*. 2012 Jan;57(1):133-41. doi: 10.1007/s10620-011-1955-9. Epub 2011 Nov 6.
310. Park JJ, **Cheon JH.**, Malignant small bowel obstruction: the last frontier for gastrointestinal stenting, *J Gastroenterol Hepatol*. 2012 Jul;27(7):1136-7. doi: 10.1111/j.1440-1746.2012.07162.x. **(corresponding author)**
311. Park SJ, **Cheon JH.**, Ye BD, Choi CH, Kim YS, Kim YH, Kim JS, Jeon YT, Park YS, Han DS, Yang SK, Kim WH., [A survey of actual clinical application patterns in Korean diagnostic guidelines for inflammatory bowel disease], *Korean J Gastroenterol*. 2012 Nov;60(5):292-9. doi: 10.4166/kjg.2012.60.5.292. **(corresponding author)**
312. Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, **Cheon JH.**, Choi CH, Kim YH, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases., [Guidelines for the management of Crohn's disease], *Korean J Gastroenterol*. 2012 Feb;59(2):141-79. doi: 10.4166/kjg.2012.59.2.141. **(corresponding author)**
313. **Cheon JH.**, Han DS, Park JY, Ye BD, Jung SA, Park YS, Kim YS, Kim JS, Nam CM, Kim YN, Yang SK, Kim WH; Korean IBD Study Group., Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet's disease, *Inflamm Bowel Dis*. 2011 Feb;17(2):605-13. doi: 10.1002/ibd.21313.
314. Jang HW, **Cheon JH.**, Nam CM, Moon CM, Lee JH, Jeon SM, Park JJ, Kim TI, Kim WH., Factors affecting insertion time for colonoscopy performed under intramuscular analgesia in patients with history of colorectal resection, *Surg Endosc*. 2011 Jul;25(7):2316-22. doi: 10.1007/s00464-010-1555-3. Epub 2011 Feb 7. **(corresponding author)**
315. Jeon SM, Lee JH, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Feasibility of salvage endoscopic mucosal resection by using a cap for remnant rectal carcinoids after primary EMR, *Gastrointest Endosc*. 2011 May;73(5):1009-14. doi: 10.1016/j.gie.2010.12.029. Epub 2011 Feb 12. **(corresponding author)**
316. Jung ES, Kim SW, Moon CM, Shin DJ, Son NH, Kim ES, Lee HJ, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Relationships between genetic polymorphisms of triggering receptor expressed on myeloid cells-1 and inflammatory bowel diseases in the Korean population, *Life Sci*. 2011 Aug 29;89(9-10):289-94. doi: 10.1016/j.lfs.2011.06.018. Epub 2011 Jul 7. **(corresponding author)**
317. Jung YS, Kim SW, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease, *Inflamm Bowel Dis*. 2011 Oct;17(10):2130-7. doi: 10.1002/ibd.21600. Epub 2011 Jan 6.
318. Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, Kim WH, **Cheon JH.**, Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease, *Inflamm Bowel Dis*. 2011 Jul;17(7):1594-602. doi: 10.1002/ibd.21517. Epub 2010 Nov 8. **(corresponding author)**
319. Kim BJ, Choi YS, Jang BI, Park YS, Kim WH, Kim YS, Jung SA, Han DS, Kim JS, Choi JH, Choi CH, Jeon YT, **Cheon JH.**, Ye BD, Yang SK, Kim YH., Prospective evaluation of the clinical utility of interferon- γ assay in the differential diagnosis of intestinal tuberculosis and Crohn's disease, *Inflamm Bowel Dis*. 2011 Jun;17(6):1308-13. doi: 10.1002/ibd.21490. Epub 2010 Nov 4.

320. Kim JH, Kim YS, **Cheon JH**, Lee SK, Kim TI, Myoung S, Kim WH., Influence of the insertion time and number of polyps on miss rate in colonoscopy, *Scand J Gastroenterol*. 2011 May;46(5):634-9. doi: 10.3109/00365521.2011.558111. Epub 2011 Mar 4.
321. Kim SW, Kim ES, Moon CM, Park JJ, Kim TI, Kim WH, **Cheon JH**., Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease, *Gut*. 2011 Nov;60(11):1527-36. doi: 10.1136/gut.2011.238477. Epub 2011 Jun 14. **(corresponding author)**
322. Kim YS, Kim YH, Kim WH, Kim JS, Park YS, Yang SK, Ye BD, Jang BI, Jung SA, Jeon YT, **Cheon JH**, Choi YS, Choi JH, Kim BJ, Choi CH, Han DS., Diagnostic utility of anti-Saccharomyces cerevisiae antibody (ASCA) and Interferon- γ assay in the differential diagnosis of Crohn's disease and intestinal tuberculosis, *Clin Chim Acta*. 2011 Aug 17;412(17-18):1527-32. doi: 10.1016/j.cca.2011.04.029. Epub 2011 May 6.
323. Lee BI, Choi H, Choi KY, Byeon JS, Jang HJ, Eun CS, **Cheon JH**, Shin SJ, Kim JO, Lee MS, Choi JH., Clinical characteristics of small bowel tumors diagnosed by double-balloon endoscopy: KASID multi-center study, *Dig Dis Sci*. 2011 Oct;56(10):2920-7. doi: 10.1007/s10620-011-1839-z. Epub 2011 Aug 4. **(corresponding author)**
324. Lee HJ, Hong SP, **Cheon JH**, Kim TI, Min BS, Kim NK, Kim WH., Long-term outcome of palliative therapy for malignant colorectal obstruction in patients with unresectable metastatic colorectal cancers: endoscopic stenting versus surgery, *Gastrointest Endosc*. 2011 Mar;73(3):535-42. doi: 10.1016/j.gie.2010.10.052. Epub 2011 Jan 22.
325. Lee JH, Hong SP, Jeon TJ, Kang GH, Choi WC, Jeon SM, Moon CM, Park JJ, **Cheon JH**, Kim TI, Kim WH., Should a colonoscopy be recommended for healthy individuals with increased carcinoembryonic antigen levels? A case-control study, *Dig Dis Sci*. 2011 Aug;56(8):2396-403. doi: 10.1007/s10620-011-1606-1. Epub 2011 Feb 17. **(corresponding author)**
326. Park JJ, **Cheon JH**, Kwon JE, Shin JK, Jeon SM, Bok HJ, Lee JH, Moon CM, Hong SP, Kim TI, Kim H, Kim WH., Clinical outcomes and factors related to resectability and curability of EMR for early colorectal cancer, *Gastrointest Endosc*. 2011 Dec;74(6):1337-46. doi: 10.1016/j.gie.2011.07.069. **(corresponding author)**
327. Park JJ, **Cheon JH**., Small bowel evaluation in asymptomatic fecal immunochemical test-positive patients with a negative colonoscopy: is it necessary?, *Dig Dis Sci*. 2011 Oct;56(10):2773-5. doi: 10.1007/s10620-011-1837-1. **(corresponding author)**
328. Shin JK, **Cheon JH**, Lim JS, Park JJ, Moon CM, Jeon SM, Lee JH, Hong SP, Kim TI, Kim WH., Long-term outcomes of obscure gastrointestinal bleeding after CT enterography: does negative CT enterography predict lower long-term rebleeding rate?, *J Gastroenterol Hepatol*. 2011 May;26(5):901-7. doi: 10.1111/j.1440-1746.2010.06577.x. **(corresponding author)**
329. Yoon JY, **Cheon JH**, Park JJ, Hong SP, Kim TI, Kim WH., Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis, *J Gastroenterol Hepatol*. 2011 Jul;26(7):1114-22. doi: 10.1111/j.1440-1746.2011.06688.x.
330. Yoon JY, Jung YS, Hong SP, Kim TI, Kim WH, **Cheon JH**., Clinical outcomes and risk factors for technical and clinical failures of self-expandable metal stent insertion for malignant colorectal obstruction, *Gastrointest Endosc*. 2011 Oct;74(4):858-68. doi: 10.1016/j.gie.2011.05.044. Epub 2011 Aug 20. **(corresponding author)**
331. Yoon JY, Jung YS, Hong SP, Kim TI, Kim WH, **Cheon JH**., Outcomes of secondary stent-in-stent self-expandable metal stent insertion for malignant colorectal obstruction, *Gastrointest Endosc*. 2011 Sep;74(3):625-33. doi: 10.1016/j.gie.2011.05.025. Epub 2011 Jul 18. **(corresponding author)**
332. Cheung DY, Lee IS, Chang DK, Kim JO, **Cheon JH**, Jang BI, Kim YS, Park CH, Lee KJ, Shim KN, Ryu JK, Do JH, Moon JS, Ye BD, Kim KJ, Lim YJ, Choi MG, Chun HJ; Korean Gut Images Study Group., Capsule endoscopy in small bowel tumors: a multicenter Korean study, *J Gastroenterol Hepatol*. 2010 Jun;25(6):1079-86. doi: 10.1111/j.1440-1746.2010.06292.x.
333. Chung JW, **Cheon JH**, Lee KJ, Kim JS, Jang SJ, Yang WI, Kim TI, Kim WH., [Aplastic anemia with trisomy 8 and trisomy 9 in intestinal behcets disease], *Korean J Gastroenterol*. 2010 Apr;55(4):256-60. doi: 10.4166/kjg.2010.55.4.256.
334. Chung JW, **Cheon JH**, Park JJ, Jung ES, Choi EH, Kim H., Development and validation of a novel prognostic scoring model for ischemic colitis, *Dis Colon Rectum*. 2010 Sep;53(9):1287-94. doi: 10.1007/DCR.0b013e3181e74171. **(corresponding author)**
335. Chung MJ, **Cheon JH**, Kim SU, Park JJ, Kim TI, Kim NK, Kim WH., Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease, *J Clin Gastroenterol*. 2010 Jul;44(6):e116-22. doi: 10.1097/MCG.0b013e3181c8a50f. **(corresponding author)**
336. Jang BI, Lee SH, Moon JS, Cheung DY, Lee IS, Kim JO, **Cheon JH**, Park CH, Byeon JS, Park YS, Shim KN, Kim YS, Kim KJ, Lee KJ, Ryu JK, Chang DK, Chun HJ, Choi MG., Inter-observer agreement on the interpretation of capsule endoscopy findings based on capsule endoscopy structured terminology: a multicenter study by the Korean Gut Image Study Group, *Scand J Gastroenterol*. 2010 Mar;45(3):370-4. doi: 10.3109/00365520903521574.
337. Jung KS, Park JJ, Chon YE, Jung ES, Lee HJ, Jang HW, Lee KJ, Lee SH, Moon CM, Lee JH, Shin JK, Jeon SM, Hong SP, Kim TI, Kim WH, **Cheon JH**., Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment

- for Clostridium difficile-associated Diarrhea, Gut Liver. 2010 Sep;4(3):332-7. doi: 10.5009/gnl.2010.4.3.332. Epub 2010 Sep 24. **(corresponding author)**
338. Jung YS, **Cheon JH**, Park JJ, Moon CM, Kim ES, Lee JH, Kim SW, Kim JH, Hong SP, Kim TI, Kim WH., Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs, J Hum Genet. 2010 Feb;55(2):121-3. doi: 10.1038/jhg.2009.125. Epub 2009 Dec 4. **(corresponding author)**
339. Kim ES, **Cheon JH**, Park JJ, Moon CM, Hong SP, Kim TI, Kim WH., Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: focus on pain perception, J Gastroenterol Hepatol. 2010 Jul;25(7):1232-8. doi: 10.1111/j.1440-1746.2010.06338.x. **(corresponding author)**
340. Kim HM, Kim YJ, Kim HJ, Park S, Park JY, Shin SK, **Cheon JH**, Lee SK, Lee YC, Park SW, Bang S, Song SY., A Pilot Study of Sequential Capsule Endoscopy Using MiroCam and PillCam SB Devices with Different Transmission Technologies, Gut Liver. 2010 Jun;4(2):192-200. doi: 10.5009/gnl.2010.4.2.192. Epub 2010 Jun 16. **(corresponding author)**
341. Kim JH, **Cheon JH**, Hong SS, Eun CS, Byeon JS, Hong SY, Kim BY, Kwon SH, Kim SW, Han DS, Yang SK, Kim WH., Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study, J Clin Gastroenterol. 2010 Nov-Dec;44(10):e242-8. doi: 10.1097/MCG.0b013e3181d6baf5. **(corresponding author)**
342. Kim SG, Song HJ, Choi IJ, Cho JY, Jung HY, Keum B, **Cheon JH**, Lee YC, Kim JG, Park SK, Park BJ, Jung HC; Korean College of Helicobacter and Upper Gastrointestinal Research., A Planned Prospective, Randomized, Placebo-Controlled Multicenter Trial Assessing the Effect of Helicobacter pylori Eradication on the Healing of Iatrogenic Ulcer after Endoscopic Resection of Gastric Neoplasm, Gut Liver. 2010 Dec;4(4):514-7. doi: 10.5009/gnl.2010.4.4.514. Epub 2010 Dec 17. **(corresponding author)**
343. Kim SW, Kim HM, Yang KM, Kim SA, Kim SK, An MJ, Park JJ, Lee SK, Kim TI, Kim WH, **Cheon JH**., Bifidobacterium lactis inhibits NF-kappaB in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice, Inflamm Bowel Dis. 2010 Sep;16(9):1514-25. doi: 10.1002/ibd.21262.
344. Kim YJ, **Cheon JH**, Lee SK, Kim JH, Lee YC., Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study, J Korean Med Sci. 2010 Apr;25(4):583-8. doi: 10.3346/jkms.2010.25.4.583. Epub 2010 Mar 19. **(corresponding author)**
345. Lee JH, **Cheon JH**, Kim ES, Chung MJ, Kang W, Kim DH, Ha YJ, Park JJ, Kim TI, Kim WH., The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis, Dig Dis Sci. 2010 May;55(5):1406-12. doi: 10.1007/s10620-009-0847-8. Epub 2009 Jun 9. **(corresponding author)**
346. Lee JH, **Cheon JH**, Moon CM, Park JJ, Hong SP, Kim TI, Kim WH., Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older?, Digestion. 2010;81(4):237-43. doi: 10.1159/000253850. Epub 2010 Jan 29. **(corresponding author)**
347. Lee JM, **Cheon JH**, Park JJ, Moon CM, Kim ES, Kim TI, Kim WH., Effects of Hyosine N-butyl bromide on the detection of polyps during colonoscopy, Hepatogastroenterology. 2010 Jan-Feb;57(97):90-4. **(corresponding author)**
348. Moon CM, **Cheon JH**, Choi EH, Kim ES, Park JJ, Han SY, Kim DH, Kim TI, Kim WH., Advanced synchronous adenoma but not simple adenoma predicts the future development of metachronous neoplasia in patients with resected colorectal cancer, J Clin Gastroenterol. 2010 Aug;44(7):495-501. doi: 10.1097/MCG.0b013e3181d6bd70. **(corresponding author)**
349. Moon CM, **Cheon JH**, Kim SW, Shin DJ, Kim ES, Shin ES, Kang Y, Park JJ, Hong SP, Nam SY, Kim TI, Kim WH., Association of signal transducer and activator of transcription 4 genetic variants with extra-intestinal manifestations in inflammatory bowel disease, Life Sci. 2010 Apr 24;86(17-18):661-7. doi: 10.1016/j.lfs.2010.02.016. Epub 2010 Feb 20.
350. Moon CM, **Cheon JH**, Shin JK, Jeon SM, Bok HJ, Lee JH, Park JJ, Hong SP, Kim TI, Kim NK, Kim WH., Prediction of free bowel perforation in patients with intestinal Behçet's disease using clinical and colonoscopic findings, Dig Dis Sci. 2010 Oct;55(10):2904-11. doi: 10.1007/s10620-009-1095-7. Epub 2010 Jan 22.
351. Park HN, Park JJ, **Cheon JH**, Hyung WJ, Cho SH, Kim KH, Kim TI, Kim WH., [Nonrotation of the prearterial segment of midgut presenting as duodenal obstruction in a 60-year-old man], Korean J Gastroenterol. 2010 Apr;55(4):252-5. doi: 10.4166/kjg.2010.55.4.252.
352. Park JH, Byeon JS, Shin WG, Yoon YH, **Cheon JH**, Lee KJ, Park J; Korean Society of Neurogastroenterology and Motility., [Diagnosis of irritable bowel syndrome: a systematic review], Korean J Gastroenterol. 2010 May;55(5):308-15. doi: 10.4166/kjg.2010.55.5.308.
353. Park JJ, **Cheon JH**, Kim HM, Park HS, Moon CM, Lee JH, Hong SP, Kim TI, Kim WH., Negative capsule endoscopy without subsequent enteroscopy does not predict lower long-term rebleeding rates in patients with obscure GI bleeding, Gastrointest Endosc. 2010 May;71(6):990-7. doi: 10.1016/j.gie.2009.12.009. Epub 2010 Mar 20. **(corresponding author)**
354. Park S, **Cheon JH**, Park JJ, Moon CM, Hong SP, Lee SK, Kim TI, Kim WH., Comparison of efficacies between stents for malignant colorectal obstruction: a randomized, prospective study, Gastrointest Endosc. 2010 Aug;72(2):304-10. doi: 10.1016/j.gie.2010.02.046. Epub 2010 Jun 19. **(corresponding author)**

355. Shin JK, **Cheon JH**, Kim ES, Yoon JY, Lee JH, Jeon SM, Bok HJ, Park JJ, Moon CM, Hong SP, Lee YC, Kim WH., Predictive capability of anorectal physiologic tests for unfavorable outcomes following biofeedback therapy in dyssynergic defecation, *J Korean Med Sci*. 2010 Jul;25(7):1060-5. doi: 10.3346/jkms.2010.25.7.1060. Epub 2010 Jun 17. **(corresponding author)**
356. Shin SJ, Lee SK, Kim TI, **Cheon JH**, Kim ES, Kim BC, Park S, Kim WH., Chronological changes in the systemic manifestations of intestinal Behçet's disease and their significance in diagnosis, *Int J Colorectal Dis*. 2010 Nov;25(11):1371-6. doi: 10.1007/s00384-010-0968-8. Epub 2010 Jun 8. **(corresponding author)**
357. Song HJ, Kim JY, Jung SA, Kim SE, Park HS, Jeong Y, Hong SP, **Cheon JH**, Kim WH, Kim HJ, Ye BD, Yang SK, Kim SW, Shin SJ, Kim HS, Sung JK, Kim EY., Effect of probiotic *Lactobacillus* (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study, *J Korean Med Sci*. 2010 Dec;25(12):1784-91. doi: 10.3346/jkms.2010.25.12.1784. Epub 2010 Nov 24. **(corresponding author)**
358. An MJ, **Cheon JH**, Kim SW, Kim ES, Kim TI, Kim WH., Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts, *Cancer Lett*. 2009 Jun 28;279(1):93-100. doi: 10.1016/j.canlet.2009.01.026. Epub 2009 Feb 18. **(corresponding author)**
359. An MJ, **Cheon JH**, Kim SW, Park JJ, Moon CM, Han SY, Kim ES, Kim TI, Kim WH., Bovine colostrum inhibits nuclear factor kappaB-mediated proinflammatory cytokine expression in intestinal epithelial cells, *Nutr Res*. 2009 Apr;29(4):275-80. doi: 10.1016/j.nutres.2009.03.011. **(corresponding author)**
360. **Cheon JH**, Kim ES, Shin SJ, Kim TI, Lee KM, Kim SW, Kim JS, Kim YS, Choi CH, Ye BD, Yang SK, Choi EH, Kim WH., Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers, *Am J Gastroenterol*. 2009 Oct;104(10):2492-9. doi: 10.1038/ajg.2009.331. Epub 2009 Jun 16.
361. **Cheon JH**, Kim JH, Kim BY, Kim SW, Hong SY, Eun CS, Hong SS, Byeon JS, Kim TI, Han DS, Yang SK, Lee KR, Kim WH., Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases, *Hepatogastroenterology*. 2009 Mar-Apr;56(90):421-3. **(1st author)**
362. **Cheon JH**, Shin SJ, Kim SW, Lee KM, Kim JS, Kim WH; IBD Study Group of the Korean Association of the Study of Intestinal Diseases., [Diagnosis of intestinal Behçet's disease], *Korean J Gastroenterol*. 2009 Mar;53(3):187-93. **(corresponding author)**
363. Kim DH, **Cheon JH**, Moon CM, Park JJ, Han SY, Kim ES, Chung MJ, Lee JH, Jung MK, Lee SH, Son JW, Kim TI, Kim WH., [Clinical efficacy of nonsurgical treatment of Crohn's disease-related intraabdominal abscess], *Korean J Gastroenterol*. 2009 Jan;53(1):29-35.
364. Kim JH, Lee YC, Kim H, Song KH, Lee SK, **Cheon JH**, Kim H, Hyung WJ, Noh SH, Kim CB, Chung JB., Endoscopic resection for undifferentiated early gastric cancer, *Gastrointest Endosc*. 2009 Apr;69(4):e1-9. doi: 10.1016/j.gie.2008.10.040.
365. Park JJ, **Cheon JH**, Kim BY, Kim DH, Kim ES, Kim TI, Lee KR, Kim WH., Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease, *Dig Dis Sci*. 2009 Jul;54(7):1525-31. doi: 10.1007/s10620-008-0514-5. Epub 2008 Oct 31. **(corresponding author)**
366. Shin DY, **Cheon JH**, Park JJ, Kim H, Kim TI, Lee YC, Kim NK, Kim WH., [Serial episodes of gastric and cecal perforation in a patient with Behçet's disease involving the whole gastrointestinal tract: a case report], *Korean J Gastroenterol*. 2009 Feb;53(2):106-10.
367. Yi SW, **Cheon JH**, Kim JH, Lee SK, Kim TI, Lee YC, Kim WH., The prevalence and clinical characteristics of esophageal involvement in patients with Behçet's disease: a single center experience in Korea, *J Korean Med Sci*. 2009 Feb;24(1):52-6. doi: 10.3346/jkms.2009.24.1.52. Epub 2009 Feb 28. **(corresponding author) (1st author)**
368. Baik SH, Lee WJ, Rha KH, Kim NK, Sohn SK, Chi HS, Cho CH, Lee SK, **Cheon JH**, Ahn JB, Kim WH., Robotic total mesorectal excision for rectal cancer using four robotic arms, *Surg Endosc*. 2008 Mar;22(3):792-7. doi: 10.1007/s00464-007-9663-4. Epub 2007 Nov 20. **(corresponding author) (1st author)**
369. **Cheon JH**, Kim JH, Lee SK, Kim TI, Kim WH, Lee YC., *Helicobacter pylori* eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study, *Helicobacter*. 2008 Dec;13(6):564-71. doi: 10.1111/j.1523-5378.2008.00647.x. **(1st author)**
370. Han JY, **Cheon JH**, Kim DH, Chon HJ, Kim SK, Kim TI, Min YH, Kim WH., [Ileal mucormycosis diagnosed by colonoscopy in a patient with acute myeloid leukemia], *Korean J Gastroenterol*. 2008 Sep;52(3):179-82.
371. Kim BC, **Cheon JH**, Kim TI, Kim WH., Risk factors and the role of bedside colonoscopy for lower gastrointestinal hemorrhage in critically ill patients, *Hepatogastroenterology*. 2008 Nov-Dec;55(88):2108-11.
372. Kim BC, **Cheon JH**, Lee SK, Kim TI, Kim H, Kim WH., Needle knife-assisted endoscopic polypectomy for a large inflammatory fibroid colon polyp by making its stalk into an omega shape using an endoloop, *Yonsei Med J*. 2008 Aug 30;49(4):680-6. doi: 10.3349/ymj.2008.49.4.680. **(corresponding author)**
373. Kim ES, Hong SY, Lee HK, Kim SW, An MJ, Kim TI, Lee KR, Kim WH, **Cheon JH**, Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells, *Oncol Rep*. 2008 Dec;20(6):1321-7. **(corresponding author)**
374. Kim JH, **Cheon JH**, Kim TI, Baik SH, Kim NK, Kim H, Kim WH., Effectiveness of radical surgery after incomplete

- endoscopic mucosal resection for early colorectal cancers: a clinical study investigating risk factors of residual cancer, *Dig Dis Sci*. 2008 Nov;53(11):2941-6. doi: 10.1007/s10620-008-0248-4. Epub 2008 Mar 21. **(corresponding author)**
375. Kim JH, **Cheon JH**, Kim WH., [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease], *Korean J Gastroenterol*. 2008 May;51(5):291-7. (co-1st author)
376. Kim JH, **Cheon JH**, Park S, Kim BC, Lee SK, Kim TI, Kim WH., Relationship between disease location and age, obesity, and complications in Korean patients with acute diverticulitis: a comparison of clinical patterns with those of Western populations, *Hepatogastroenterology*. 2008 May-Jun;55(84):983-6. **(corresponding author)**
377. Kim YJ, Lee SK, **Cheon JH**, Kim TI, Lee YC, Kim WH, Chung JB, Yi SW, Park S., [Efficacy of endoscopic resection for small rectal carcinoid: a retrospective study], *Korean J Gastroenterol*. 2008 Mar;51(3):174-80.
378. Lee SH, **Cheon JH**, Kim JH, Park JP, Lee SK, Lee YC., [Non-healing iatrogenic gastric ulcers after endoscopic mucosal resection for gastric epithelial neoplasia: report of two cases], *Korean J Gastroenterol*. 2008 Feb;51(2):127-31.
379. Park JJ, **Cheon JH**., [Intestinal tuberculosis mimicking colon cancer], *Korean J Gastroenterol*. 2008 Oct;52(4):203-6.
380. Park SY, Lee SK, Kim BC, Han J, Kim JH, **Cheon JH**, Kim TI, Kim WH., Efficacy of chromoendoscopy with indigocarmine for the detection of ascending colon and cecum lesions, *Scand J Gastroenterol*. 2008;43(7):878-85. doi: 10.1080/00365520801935442.
381. Woo HG, Park ES, **Cheon JH**, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, Yoon JH, Lee HS, Kim CY, Yi NJ, Suh KS, Lee KU, Chu IS, Roskams T, Thorgeirsson SS, Kim YJ., Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma, *Clin Cancer Res*. 2008 Apr 1;14(7):2056-64. doi: 10.1158/1078-0432.CCR-07-1473.
382. **Cheon JH**, Kim JS, Ko SJ, Ye BD, Kim SG, Jung HC, Song IS., Risk factors for upper gastrointestinal rebleeding in critically ill patients, *Hepatogastroenterology*. 2007 Apr-May;54(75):766-9. **(1st author)**
383. **Cheon JH**, Kim WH., Recent advances of endoscopy in inflammatory bowel diseases, *Gut Liver*. 2007 Dec;1(2):118-25. doi: 10.5009/gnl.2007.1.2.118. Epub 2007 Dec 31. **(corresponding author) (1st author)**
384. **Cheon JH**, Song HJ, Kim JS, Park KJ, Kim WH, Jung HC, Song IS., Recurrent lower gastrointestinal bleeding from congenital arteriovenous malformation in the terminal ileum mimicking intestinal varicosis: a case report, *J Korean Med Sci*. 2007 Aug;22(4):746-9. doi: 10.3346/jkms.2007.22.4.746. **(corresponding author) (1st author)**
385. Kim JH, Song KS, Youn YH, Lee YC, **Cheon JH**, Song SY, Chung JB., Clinicopathologic factors influence accurate endosonographic assessment for early gastric cancer, *Gastrointest Endosc*. 2007 Nov;66(5):901-8. doi: 10.1016/j.gie.2007.06.012.
386. Kim SU, **Cheon JH**, Lim JS, Paik SH, Kim SK, Lee SK, Lee YC, Kim WH., [Massive gastrointestinal bleeding due to aneurysmal rupture of ileo-colic artery in a patient with Behcet's disease], *Korean J Gastroenterol*. 2007 Jun;49(6):400-4.
387. **Cheon JH**, Kim JS, Kim JM, Kim N, Jung HC, Song IS., Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis, *Inflamm Bowel Dis*. 2006 Dec;12(12):1152-61. doi: 10.1097/01.mib.0000235830.94057.c6.
388. **Cheon JH**, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS., Long-term outcomes after *Helicobacter pylori* eradication with second-line, bismuth-containing quadruple therapy in Korea, *Eur J Gastroenterol Hepatol*. 2006 May;18(5):515-9. doi: 10.1097/00042737-200605000-00010. **(1st author)**
389. **Cheon JH**, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS., Efficacy of moxifloxacin-based triple therapy as second-line treatment for *Helicobacter pylori* infection, *Helicobacter*. 2006 Feb;11(1):46-51. doi: 10.1111/j.0083-8703.2006.00371.x. **(1st author)**
390. **Cheon JH**, Kim SG, Kim JM, Kim N, Lee DH, Kim JS, Jung HC, Song IS., Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for *Helicobacter pylori* eradication despite high in vitro susceptibility, *J Gastroenterol Hepatol*. 2006 Oct;21(10):1590-5. doi: 10.1111/j.1440-1746.2006.04291.x. **(corresponding author) (1st author)**
391. Choi YS, **Cheon JH**, Lee JY, Kim SG, Kim JS, Kim N, Lee DH, Kim JM, Jung HC, Song IS., [The trend of eradication rates of first-line triple therapy for *Helicobacter pylori* infection: single center experience for recent eight years], *Korean J Gastroenterol*. 2006 Sep;48(3):156-61. **(corresponding author) (1st author)**
392. Chung GE, **Cheon JH**, Lee JY, Ye BD, Kim SG, Kim JS, Jung HC, Song IS., [Efficacy of combination of intravenous cyclosporin A and steroid therapy versus prolonged intravenous steroid therapy alone in patients with severe ulcerative colitis refractory to initial intravenous steroid therapy], *Korean J Gastroenterol*. 2006 Oct;48(4):263-8. **(corresponding author) (1st author)**
393. **Cheon JH**, Kim N, Lee DH, Kim JW, Hwang JH, Park YS, Kim JM, Suh SO, Jung HC, Song IS., [Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for *Helicobacter pylori* infection], *Korean J Gastroenterol*. 2005 Feb;45(2):111-7. **(corresponding author) (1st author)**
394. Cho SH, **Cheon JH**, Lee SW, Park HS, Kim SH, Park SJ, Lee WJ, Hong EK, Park JW., [A case of osteoclast-like giant cell tumor of the pancreas], *Korean J Gastroenterol*. 2005 Jun;45(6):441-5. **(corresponding author) (1st author)**
395. Lee JH, **Cheon JH**, Park MJ, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS., [The trend of eradication rates of

- second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years], Korean J Gastroenterol. 2005 Aug;46(2):94-8. (**corresponding author**) (**1st author**)
396. **Cheon JH**, Park JW, Park KW, Kim YI, Kim SH, Lee WJ, Park HS, Park SJ, Hong EK, Kim CM., [The clinical report of 1,078 cases of hepatocellular carcinomas: National Cancer Center experience], Korean J Hepatol. 2004 Dec;10(4):288-97. (**corresponding author**) (**1st author**)
397. Hwang JH, Yoon YB, Kim YT, **Cheon JH**, Jeong JB., Risk factors for recurrent cholangitis after initial hepatolithiasis treatment, J Clin Gastroenterol. 2004 Apr;38(4):364-7. doi: 10.1097/00004836-200404000-00012. (**corresponding author**) (**1st author**)
398. Yoo SJ, **Cheon JH**, Lee SW, Jung YS, Lee SH, Park JW, Hong EK, Kim CM., [Extrahepatic metastasis of hepatocellular carcinoma to the nasal cavity manifested as massive epistaxis: a case report], Korean J Hepatol. 2004 Sep;10(3):228-32.

Industry sponsored Clinical Trials

| Period | Sponsor | IP | Phase | Indication | Role |
|---------------|-----------------------------|--|--------------|-------------------|-------------|
| 2023-ongoing | ABIVAX | ABX464 | 3 | UC | PI |
| 2023-ongoing | Morphic Therapeutic | MORF-057-202 | 2b | UC | PI |
| 2023-ongoing | Jassen | Guselkumab, Golimumab | 3 | UC | PI |
| 2023-ongoing | Jassen | Guselkumab | 3 | UC | PI |
| 2018-ongoing | AbbVie | Risankizumab, M16-066 (유지/연장) | 3 | UC | PI |
| 2017-ongoing | Galapagos | Filgotinib, GS-US-419-3899 (연장) | 3 | UC | PI |
| 2017-ongoing | AbbVie | ABT-494, M14-533 | 3 | UC | PI |
| 2023-ongoing | Jassen | Guselkumab, Golimumab, | 3 | CD | PI |
| 2018~ongoing | Celgene | Ozanimod | 3 | CD | PI |
| 2022-2023 | Jassen | Guselkumab | 3 | CD | PI |
| 2020-2022 | Pfize | Xeljanz | PMS | UC | PI |
| 2018-2023 | Jassen | Guselkumab | 2b/3 | CD | PI |
| 2018-2022 | AbbVie | (Upadacitinib) M14-698 | 2b/3 | UC | PI |
| 2019-2024 | Jassen | (Upadacitinib) M14-697 | 2b/3 | UC | PI |
| 2021-2024 | Boehringer Ingelheim | (Upadacitinib) M14-696 | 2a | CD | PI |
| 2015-2022 | Anterogen | (Upadacitinib) M14-695 | 1 | CD | PI |
| 2017-2021 | AbbVie | (Upadacitinib) M14-694 | 3 | CD | PI |
| 2017-2021 | AbbVie | (Upadacitinib) M14-693 | 3 | CD | PI |
| 2014-2021 | Janssen | (Upadacitinib) M14-692 | cohort | UC | PI |
| 2018-2023 | Pfizer | (Upadacitinib) M14-691 | 3b/4 | UC | PI |
| 2014-2026 | Roche | (Upadacitinib) M14-690 | 3 | UC | PI |
| 2014-2020 | Roche | (Upadacitinib) M14-689 | 3 | UC | PI |
| 2014-2020 | Roche | (Upadacitinib) M14-688 | 3 | UC | PI |
| 2017-2022 | AbbVie | (Upadacitinib) M14-686 (Upadacitinib) M14-687 | 2b/3 | UC | PI |
| 2020-2023 | Theravance | (Upadacitinib) M14-685 | 2b/3 | UC | PI |

| | | | | | |
|----------------|---------------------------------|--|------|-------------|----|
| 2020-2023 | Theravance | (Upadacitinib) M14-684 | 2b/3 | UC | PI |
| 2020-2023 | Theravance | (Upadacitinib) M14-683 | 2 | CD | PI |
| 2017-2020 | Gilead | (Upadacitinib) M14-682 | 3 | CD | PI |
| 2017-2020 | Gilead | (Upadacitinib) M14-681 | 3 | CD | PI |
| 2017-2022 | Takeda | (Upadacitinib) M14-680 | 4 | UC, CD | PI |
| 2015-2022 | Jassen | (Upadacitinib) M14-679 | 3 | UC | PI |
| 2017-2020 | Gilead | (Upadacitinib) M14-677 (Upadacitinib) M14-678 | 2b/3 | UC | PI |
| 2015-2021 | Roche | (Upadacitinib) M14-676 | 3 | CD | PI |
| 2019-2023 | AbbVie | ABT-494, (Upadacitinib) M14-675 | 3 | UC | PI |
| 2019-2020 | Koreapharma | Plenvu Power, Clicool power | 4 | colonoscopy | PI |
| 2017-2020 | Pfizer | PF-06651600 /PF-06700841 | 2b | UC | PI |
| 2015-2020 | AbbVie | AMORE | PMS | bechet | PI |
| 2018-2025 | Shire | SHP647 (LTE) | 3 | UC | PI |
| 2018-2025 | Shire | SHP647(maintanance) | 3 | UC | PI |
| 2018-2025 | Shire | SHP647(induction) | 3 | UC | PI |
| 2014-2026 | Celltrion | Remsima | 4 | UC, CD | PI |
| 2018.7-2024.02 | AbbVie | M14-430 (Upadacitinib) | 3 | CD | PI |
| 2018.7-2020 | AbbVie | M14-431 (Upadacitinib) | 3 | CD | PI |
| 2018.7-2020 | AbbVie | M14-433 (Upadacitinib) | 3 | CD | PI |
| 2016-2020 | Anterogen | ALLO-ASC(extension) | 1 | CD | PI |
| 2014-2020 | Pfizer | CP-690,550 (Tofacitinib) | 3 | UC | PI |
| 2018-2021 | Boehringer Ingelheim | BI 655130 (spesolimab) (long term extension) | 2b/3 | UC | PI |
| 2018-2021 | Boehringer Ingelheim | BI 655130 (spesolimab) | 2b/3 | UC | PI |
| 2017-2019 | Esiai | NA | NA | CD,UC | PI |
| 2018.12~2020.5 | JANSSEN | CNT0275CRD3007 (Udtekinumab:Adalimumab) | 3b | CD | PI |
| 2016-2020 | Anterogen | ALLO-ASC | 1 | CD,UC | PI |
| 2015-2019 | Jassen | Golimumab | PMS | UC | PI |
| 2017-2020 | Jassen | JNJ-64304500 | 2b | CD | PI |
| 2012-2019 | Jassen | Ustekinumab | 3 | CD | PI |
| 2015-2019 | Receptos | RPC1063(Ozanimod) | 3 | UC | PI |
| 2015-2020 | Takeda | Vedolizumab | 3 | CD | PI |
| 2015-2018 | Takeda | Vedolizumab/Adalimumab | 3 | UC | PI |
| 2016-2022 | Takeda | Vedolizumab(extention) | 3 | UC, CD | PI |
| 2017- | Protagonist | PTG-100 | 2b | UC | PI |
| 2016-2018 | Pfizer | PF-06480605 | 2a | UC | PI |
| 2015-2016 | Jassen | Infliximab | 3 | Behcet | PI |
| 2016-2021 | Celgene | MONGERSEN(extension) | 3 | CD | PI |
| 2015-2018 | Celgene | MONGERSEN | 3 | CD | PI |
| 2015-2018 | Takeda | Vedolizumab | 3 | UC | PI |

| | | | | | |
|-----------|---------------------|-----------------------------------|-----|--------|----|
| 2008-2016 | Takeda | MLN0002 (Vedolizumab) | 3 | UC, CD | PI |
| 2013-2016 | Celltrion | Remsima | PMS | UC, CD | PI |
| 2014-2017 | BI | BI 655130 | 2 | CD | PI |
| 2016-2017 | Gilead | GS-5745 | 2/3 | UC | PI |
| 2014-2015 | Pfizer | CP-690,550 Maintenance | 3 | UC | PI |
| 2011-2015 | Pfizer | CP-690,550 induction(Tofacitinib) | 3 | UC | PI |
| 2011-2015 | Pfizer | CP-690,550 induction(Tofacitinib) | 2 | CD | PI |
| 2011-2015 | Pfizer | CP-690,550 Maintenance | 2 | CD | PI |
| 2014-2015 | SK chemicals | YKP10811 | 2 | IBS-C | PI |
